Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Abstract 


Introduction

Coronavirus disease 2019 (COVID-19) is an illness caused by the new coronavirus severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). It has affected public health and the economy globally. Currently approved vaccines and other drug candidates could be associated with several drawbacks which urges developing alternative therapeutic approaches.

Aim

To provide a comprehensive review of anti-SARS-CoV-2 activities of plants and their bioactive compounds.

Methods

Information was gathered from diverse bibliographic platforms such as PubMed, Google Scholar, and ClinicalTrials.gov registry.

Results

The present review highlights the potential roles of crude extracts of plants as well as plant-derived small molecules in inhibiting SARS-CoV-2 infection by targeting viral or host factors essential for viral entry, polyprotein processing, replication, assembly and release. Their anti-inflammatory and antioxidant properties as well as plant-based therapies that are under development in the clinical trial phases-1 to 3 are also covered.

Conclusion

This knowledge could further help understanding SARS-CoV-2 infection and anti-viral mechanisms of plant-based therapeutics.

Free full text 


Logo of pheelsevierLink to Publisher's site
Microb Pathog. 2022 Jul; 168: 105512.
PMCID: PMC8976571
PMID: 35381324

Multifaceted roles of plant derived small molecule inhibitors on replication cycle of SARS-CoV-2

Associated Data

Supplementary Materials
Data Availability Statement

Abstract

Introduction

Coronavirus disease 2019 (COVID-19) is an illness caused by the new coronavirus severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). It has affected public health and the economy globally. Currently approved vaccines and other drug candidates could be associated with several drawbacks which urges developing alternative therapeutic approaches.

Aim

To provide a comprehensive review of anti-SARS-CoV-2 activities of plants and their bioactive compounds.

Methods

Information was gathered from diverse bibliographic platforms such as PubMed, Google Scholar, and ClinicalTrials.gov registry.

Results

The present review highlights the potential roles of crude extracts of plants as well as plant-derived small molecules in inhibiting SARS-CoV-2 infection by targeting viral or host factors essential for viral entry, polyprotein processing, replication, assembly and release. Their anti-inflammatory and antioxidant properties as well as plant-based therapies that are under development in the clinical trial phases-1 to 3 are also covered.

Conclusion

This knowledge could further help understanding SARS-CoV-2 infection and anti-viral mechanisms of plant-based therapeutics.

Keywords: SARS-CoV-2, COVID-19, Viral replication cycle, Plants, Small molecule inhibitors, Antiviral therapeutics

Abbreviations

RBD
receptor-binding domain
RBM
receptor-binding motif
aa
amino acids
nsp
non-structural protein
E
envelope protein
M
membrane protein
N
nucleocapsid
NTD
N-terminal domain
CTD
C-terminal domain
ACE2
angiotensin-converting enzyme 2
TMPRSS2
transmembrane protease serine 2
RNA
ribonucleic acid
sgRNAs
sub-genomic RNAs
gRNA
genomic RNA
ERGIC
endoplasmic reticulum-Golgi intermediate complex
LDLRA
low density lipoprotein receptor class A
SRDR
scavenger receptor cysteine-rich domain
RdRp
RNA dependent RNA polymerase
kb
kilobases
PLpro
papain-like protease
3-CLpro
3 chymotrypsin-like protease
EGCG
Epigallocatechin 3-gallate
TF
theaflavin
SF-1
superfamily-1
ADMET
absorption, digestion, metabolism, excretion, and toxicity
QGRG
Quercetin 3-glucosyl rhamnosyl galactoside
2′-O-MTase
2′-O- methyltransferase
kDa
kilodalton

1. Introduction

A newly emerged pandemic of COVID-19, caused by an infectious coronavirus SARS-CoV-2, has severely affected the entire world and remains a health threat. The emergence of new strains that evade immune responses generated by the vaccines suggests an urgent need for developing alternative therapeutic approaches to cut down the COVID-19 infection rate and related morbidity and mortalities.

COVID-19 is currently being treated with several plausible drugs including antimalarial drugs [28], antiviral drugs [83], certain immunosuppressors [70], and convalescent plasma therapy. However, these kinds of treatments are associated with several concerns, especially in patients with severe disease conditions [90]. For example, severe adverse effects such as renal impairment and hypotension were observed in critically ill patients receiving remdesivir therapy [30]. Additionally, several case studies have reported that these standard drugs exhibit drug-drug or nutrition-drug interactions into the severely infected COVID-19 patients resulting in the unrecognized source of medication errors and negative effects [2]. Therefore, it is essential to use an alternative and safer approach, such as plant-derived compounds.

Numerous scientific reports have documented the ability of plants and their secondary metabolites against SARS-CoV [91]. Despite being new virus, there are multiple in-silico studies suggesting anti-SARS- CoV-2 capability of plant-based small compounds. Additionally, in-vitro, cell culture and in-vivo clinical trials further validate and strengthen their COVID-19 suppressing potential.

2. Scope of the review

This review article aims to collect data on anti-SARS-CoV-2 activity and therapeutic potential of natural plant extracts and phytocompounds primarily based on in-silico (molecular docking and molecular dynamics) studies. An attempt has also been made to highlight in-vitro, cell culture, in-vivo and clinical trial (phase 1 to 3) studies. Several bibliographic platforms such as PubMed, Science-Direct, Google Scholar, and ClinicalTrials.gov registry were used to gather research findings and to summarize them methodically as a review.

3. Fundamentals of SARS-CoV-2 genome organization and life cycle

SARS-CoV-2 infects human lung epithelial cells by binding to the cell surface located angiotensin-converting enzyme 2 (ACE2) receptor with the help of the receptor-binding domain (RBD) of spike protein (S protein). The transmembrane serine protease 2 (TMPRSS2) is required for the priming/activation of the S-protein [35]. A high expression of ACE2 and TMPRSS2 in the gastrointestinal tract has been reported to be associated with gastrointestinal symptoms seen in COVID-19 patients. There are also a few studies describing changes in the gut microbiome of these patients compared to healthy persons [32].

More recently, it has been found that the cleavage of a multibasic site present between two subunits (S1 and S2) of S protein by furin protease is also involved in S-protein mediated efficient membrane fusion, viral entry and the transmission of SARS-CoV-2 [36,65]. The virus is internalized via directly through RBD- ACE2 interaction or membrane fusion which requires TMPRSS2 proteolytic activity [9]. It is followed by uncoating of its genome and release into the host cell cytoplasm, which undergoes translation to produce viral proteins. Non-structural proteins (NSPs) 2–16 contain RNA synthesis, proof reading, cofactor and host immune evasion activities [76,88]. A negative-sense RNA intermediate is generated for the synthesis of positive-sense strand genomic RNA (gRNA) as well as a set of shorter sub-genomic RNAs (sgRNAs). Finally, the gRNA is packaged and assembled into progeny virions at the endoplasmic reticulum-Golgi intermediate compartment (ERGIC). The sgRNAs encode structural proteins such as envelope (E), membrane (M), and nucleocapsid (N) and several accessory proteins (ORF3a, ORF6, ORF7a, ORF7b, ORF8, and other ORFs) [9,59,68,74]. (Fig. 1, Fig. 2, Fig. 3 ).

Fig. 1

Structure of the SARS-CoV-2 virus: Spike (S) is the surface glycoprotein that mediates the interaction of SARS-CoV-2 with the cell surface receptor angiotensin-converting enzyme 2 (ACE2). The membrane glycoprotein (M) and envelope (E) are embedded in the host cell-derived lipid membrane which encapsulates the viral nucleocapsid.

Fig. 2

Genome organization of SARS-CoV-2. Approximately 30 kb long viral genome comprises 10 open reading frames (ORFs) encoding 27 viral proteins. The ORF1ab encompasses about 67% of the total viral genome and encodes 16 non-structural proteins (nsps). Whereas the accessory and structural proteins are encoded by the remaining ORFs(adapted from Kim et al., 2020[116] with some modifications)

Fig. 3

The life cycle of SARS-CoV-2 and potential targets of plant-derived small molecule inhibitors (A-B) SARS-CoV- 2 spike protein binding to ACE2 followed by internalization of the virus (C) uncoating of the viral genome and its release into the cytoplasm (D-E) translation of replicase proteins (ORF1a/ab) followed by proteolysis (F–K) Replication/transcription of the viral genome. Incoming positive-strand genome generates full-length negative-strand RNA and sub-genomic RNA (sgRNAs). sgRNA translation results in both structural proteins and accessory proteins. (L–P) Structural proteins S (spike), M (membrane), E (envelope), and viral nucleocapsid complex get inserted into the ER-Golgi intermediate compartment (ERGIC) for virion assembly and release. Plant-based inhibitors (highlighted in yellow boxes) can target the majority of these steps as marked in red. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) (adapted from de Vries 2020 [117] with some modifications)

4. Virus-host interactions: Potential antiviral targets

The virus-host interactions during the virus entry, replication, and pathogenesis play a crucial role in the virus life cycle. Several viral and cellular factors facilitate this process in a coordinated manner. In SARS-CoV-2 infection, the viral spike protein interaction with host ACE2, TMPRSS2, and furin facilitate virus entry, which are thepotential drug targets for developing SARS-CoV-2 antivirals ( Figure-4 ) and are discussed below in detail.

Fig. 4

Spike, ACE2, TMPRSS2 and Furin are the targets of viral entry inhibition. Plant-based inhibitors utilize several mechanisms to block SARS-CoV-2 entry.

4.1. Spike (S) protein

Spike is a trimeric glycoprotein that mediates the binding of the virus to host cell surface-specific receptors and virus-cell membrane fusion [122]. It plays a vital role in determining host tropism and the diversity of coronaviruses (CoVs). SARS-CoV-2 is more contagious than SARS-CoV as SARS-CoV-2 spike protein interacts with ACE2 with 10–20 folds higher affinity than SARS-CoV. The receptor-binding motif (RBM) (437–508 amino acids) present in the RBD (319–541 amino acids) of the S1 subunit (13–685 amino acids) of the spike protein is majorly responsible for the binding of the virus to ACE2 [7,8,89] ( Figure-5 ). In-silico docking results showed that the phytocompounds enlisted under the spike section in Table-1 interact well with the hot-spot residues of the RBD of spike glycoprotein of SARS-CoV-2.

Fig. 5

Molecular structure of spike protein of SARS-CoV-2 and interactions with plant-based drugs. A furin cleavage site is present at the interface between S1 and S2 subunits of the spike protein. Amino acid positions of spike protein that can be interacted by different groups of plant-based inhibitors (steroids, quinones, terpenoids, flavonoids, and tannins) are also shown. Please refer Table-1 for precise details. SP- signal peptide; RBD- Receptor binding domain; RBM- Receptor binding motif; TM-transmembrane motif; FP- fusion peptide; HR1-Heptad repeat-1, HR2-heptad repeat-2; NTD- N-terminal domain, CP- cytoplasmic domain(adapted from Joshi et al., 2020[40] with some modifications).

Table 1

Interactions of plant-based small molecules with targeted SARS-CoV-2 or host proteins.

Spike Glycoprotein (viral protein)

ClassSmall molecule inhibitorsInteracting amino acids with different classes of phytocompoundsReferences

TanninsPunicalin (3-IR and −7.406 BE), punicalagin (6-IR and −7.312 BE), Pedunculagin (4-HB, 6 NBI and −7.7 BE), punigluconin (7-HB, 5-NBI and −7.9 BE), chebulagic acid (5-HB, 5-NBI and −7.5 BE), chebulinic acid (5-HB, 7-NBI and −6.5 BE), cinnamtannin-B1 (3-HB, 3-HP and −10.2 BE), 6-Glucopyranosyl procyanidin-B1 (8-HB, 1-EI and −9.9 BE), Procyanidin-B7 (2-HB, 3-HP, 2-EI and −9.6 BE), proanthocyanidin-A2 (5-HxB, 1-HP, 2-EI and −9.4 BE), ellagic acid (3 IR and −6.114 BE), gallic acid (2 IR and −4.808 BE), gallotannins (6 HB, 7-NBI, −7.4 BE).Phe40, Leu95, Gln102, Asn103, Lys187, Asp206, Val209, Asn210, Leu335, Phe342, Asn343, Pro346, Thr347, Trp349, Val367, Leu368, Tyr369, Asn370, Ser371, Ala372, Phe374, Phe377, Asp382, Phe390, Arg393, Asn394, Glu398, Gln493, Ala396, His401, Glu402, Arg403, Glu406, Gln409, Lys417, Tyr449, Tyr453, Leu455, Phe456, Tyr489, Phe490, Leu492, Gln493, Ser494, Tyr495, Gln496, Asn501, Tyr505, Asp509, Arg514, Tyr515, Lys562, Lys562, Pro565[56,66,79].
TerpenoidsGeraniol (2-HB and-5.0 BE), L-4-terpineol (2-HB and −5.1 BE), carvacrol (1-HB and −5.2 BE), limonene (12-HPI and −5.1 BE), thymol (-5.4 BE), tinosporide (2HB, 6-NBI and −6.4 BE), taraxerol (7-NBI and −7.9 BE), daturaolone (8 NBI and −7.5 BE), glycyrrhizin (7-HB, 3-NBI, −7.1 BE), friedelin (1-HB, 2-IR and −7.3 BE), tenuifolin (4-HB, 2-HP and −8.7 BE), [Upsilon]-terpinene (−4.8 BE), α-terpinene (−5.0 BE), camphene (2-HPI and −5.2 BE), camphor (2-HPI and −4.8 BE).Leu73, Asp350, Tyr385, Phe390, Asn394, Arg403, Asp405, Glu406, Arg408, Gln409, Gly416, Lys417, Tyr449, Tyr451, Leu452, Tyr453, Leu455, Phe-456, Lys458, Ser-459, Leu461, Ile468, Thr470, Ile472, Glu484, Tyr489, Phe490, Pro491, Leu492, Gln493, Ser494, Tyr495, Gly496, Asn501, Tyr505[47,56,66]
FlavonoidsPavetannin-C1 (9-HB, 4-HP, 1-EI and −11.1 BE), hesperidin (5 IR and −8.99), chrysin (9 IR and −6.87), querceitin 3-O-robinobioside (5-HB, 6-NBI, −7.9 BE), kaempferol 3 - alpha-l-arabinofuranoside 7-rhamnoside (7-HB, 2-HP and −8.7 BE), catechin gallate (5 HB, 3 HP and −6.1 BE), cinnamaldehyde (2-HB and −5.0 BE), Anthranol (1 HB, 2 HP and-9.08 BE),Apigenin (5 HB, 2 HP and -10.09 BE)Derrisin (2 HB, 2 HP and -11.04 BE)Jaceidin (2 HB, 2 HP and -10.54 BE),Lupiwighteone (1 HB, 3 HP and -9.92 BE), Luteolin (2 HB, 2 HP and -10.92 BE), Mundulinol (2 HB, 1 HP and -11.08 BE), Naringenin (2 HB, 2 HP and -10.12 BE), Rhamnetin (2 HB, 2 HP and -10.15 BE), Tamarixetin (2 HB, 1 HP and -10.33 BE), Cannflavin (1 HB, 2 HP and -9.11 BE), Methylglovanon (1 HB, 1 HP and -9.43 BE)Ser44, Leu48, Ala292,Cys301, Leu303, Ile312, Tyr313, Thr315, Asn317, Phe318, Arg319, His345, Thr347, Ala348, Trp349, Asp350, His374, Glu375, His378, Asp382, Tyr385, Gly395, Asn397, Glu398, His401, Arg403, Glu406, Tyr410, Lys417, Arg443, Ser448, Asn449, Tyr453, Arg454, Leu455, Phe456, Ser459, Glu471, Val472, Glu473, Gly474, Phe475, Phe486, Tyr484, Thr487, Asn488, Ser494, Tyr495, Gly496, Phe497, Tyr505, Tyr510, Arg514, Tyr515, Gln516, Leu517, His519, Ala520, Ala522, Asn544, Gly545, Leu546, Val595, Pro665, Ser730, Met731, Lys733, Gln762, Arg765, Ala766, Asn856, Val860, Pro863, Asp867, Asp867, Lys964, Leu966, Ser967, Phe970, Asn969, His1058.[12,47,56,57,[25], [66]]
SteroidsWithametelin (8 NBI and −8.0 BE), withanolide-A (1-HB, 7-NBI and −7.7 BE), echinacin (2-HB, 6-NBI and −7.9 BE), stigmasterol (2-IR and −7.2 BE), withanolide G (4 HB, 2 HP and −8.4 BE)Asp66, Arg67, Gln85, Val367, Asn370, Phe374, Tyr449, Leu452, Leu455, Phe456, Glu484, Tyr489, Phe490, Leu492, Gln493, Ser494.[41,56,57]
QuinoneEmodin (4 IR and −6.19), rhein (5 IR and −8.73)Asn332, Thr333, Asn353, Ser388, Val401, Asn448, Ala464, Val472, Gly474,[12]
Steroidal saponinsAsparoside-C (5 HB and −7.54 BE), asparoside-D (6 HB and −7.06 BE), shatavarin-I (Asparoside-B) (5 HB and −6.52 BE), shatavarin-X (6 HB and −6.43 BE), racemoside-A (3 HB and −6.23)Arg403, Glu406, Gln409, Gln414, Thr415, Lys417, Asp420, Lys444, Gly447, Tyr449, Tyr453, Glu484, Ser494, Gly496, Gly496, Gln498, Gly502[16]
AlkaloidChelidimerine (2 HB, 3 HP and −8.2 BE), Withanone (1 HB, 5 HP and −7.8 BE), Norsanguinarine (3 HB, 3 HP and −7.0 BE), Sanguinarine (1 HB, 4 HP and −6.8 BE), Adlumidine (3 HB, 4 HP and −6.8 BE), Somniferine (2 HB, 4 HP and −6.7 BE), Fumariline (1 HB, 3 HP and −6.4 BE)Asp66, Arg67, Leu335, Phe338, Gly339, Phe342, Asn343, Asp364, Val367, Leu368, Leu368, Asn370, Ser371, Phe374, Trp436[57]
SesquiterpeneBadrakemin acetate (3 HB, 5 HP, and −8.0 BE), Samarcandin (2 HB, 3 HP, and −7.4 BE)Leu335, Phe338, Gly339, Glu340, Asn343, Asp364, Val367, Leu368[57]
Plant lignansPinoresinol-4-O-b-d- glucopyranoside (4 HB, 3 HP, and −4.9 BE)Cys336, Phe338, Asn343, Asp364, Val367, Leu368, Ser371[57]
AnthocyaninPelargonidin 3-glucoside (4 HB, 3 HP and −6.2 BE)Cys336, Phe338, Asn343, Asn364, Val367, Leu368, Ser371[57]
Other compoundsCinnamyl acetate (3-HB and −5.2 BE), barlerinoside (7-HB, 9-NBI and −7.4 BE), deoxytubulosine (1-HB, 8-NBI and −7.2 BE)Arg403, Asp405, Glu406, Gln409, Lys417, Tyr449, Tyr453, Arg454, Leu455, Phe456, Ser469, Glu471, Glu484, Gly485, Tyr489, Phe490, Leu492, Gln493, Ser494, Gly496, Asn501, Tyr505[47,56]
Standards
Remidesvir (3 IR and −5.94 BE), chloroquine (3 IR and −8.98), hydroxychloroquine (4 IR and −7.82 BE)
Arg403, Glu406, Tyr453, Thr467, Pro468, Cys469, Gly471, Val472
[12,16,41]
[16]
ACE2 (host protein acting as CoV-2 receptor)
Class
Small molecule inhibitors
Interacting residues with different classes of phytocompounds
References
Organo-sulfurAllyl disulfide (3 IR and −12.84 BE), allyl trisulfide (2 IR and −12.76 BE), allyl (E)-1-propenyl disulfide (2 IR and −9.07 BE), allyl methyl trisulfide (2 IR and −12.50 BE), diallyl tetrasulfide (4 IR and −14.06 BE), 1,2-dithiole (2 IR and −13.21 BE), 1,2-dithiole (1 IR and −7.89), allyl (Z)-1-propenyl disulfide (T7) (2 IR and −9.04 BE), 2-vinyl-4H-1,3-dithiine (3 IR and −11.83 BE), 3-vinyl-1,2-dithiacyclohex-4-ene (3 IR and −10.57 BE), carvone (2 IR and −8.58 BE), trisulfide, 2-propenyl propyl (4 IR and −14.01 BE), methyl allyl disulfide (3 IR and −10.32 BE), diacetonalcohol (2 IR and −9.71 BE), trisulfide, (1E)-1-propenyl 2- propenyl (2 IR and −9.57 BE), allyl sulfide (3 IR and −9.38 BE), 1-propenyl methyl disulfide (2 IR and −8.06 BE), trisulfide, (1Z)-1-propenyl 2- propenyl (2 IR and −8.06 BE).Lys94, Gln98, Gln101, Gln102, Asn103, Gly205, Asp206, Glu208, Val209, Asn210, Ala396, Lys562, Ser563, Pro565, Trp566[82]
TanninsPunicalin (5 IR and −7.353 BE), punicalagin (4 IR and −7.144 BE), ellagic acid (4 IR and −6.85 BE), gallic acid (4 IR and −5.24 BE), pedunculagin (4 HB, 4 HPI and −7.2 BE), punigluconin (5 HB, 5 HPI and −6.6 BE), chebulagic acid (1 HB, 6 HPI and −6.6 BE), chebulinic acid (4 HB, 3 HPI and −6.8 BE), gallotannins (4 HB, 7 HPI and −7.1 BE).Asp30, Asn33, His34, Glu35, Glu37, Asp38, Tyr41, Ser280, Pro289, Asn290, Ile291, Asp292, Arg393, Lys353, Asp367, Ala386, Ala387, Gln388, Pro389, Arg393, Phe428, Lys441, Gln442, Thr445.[79]
FlavonoidHesperidin (4 IR and −9.167 BE), chrysin (3 IR and −7.146 BE), rutin (6 IR and −3.41 BE), vitexin (7 IR and −5.71 BE), apigenin (5 IR and −3.75 BE), quercetin (5 IR and −4.11 BE)Thr27, Lys31, His34, Glu35, Glu37, Asp38, Gln42, Asn63, Thr125, Ile126, Thr129, Asn137, Pro138, Gly139, Lys353[[12], [100]]
QuinoneEmodin (3 IR and −9.83 BE), Rhein (- 7.423 BE)Asp67, Ala71, Lys74[12]
TerpenoidThymol and iso-thymol (1 H-donor and −4.74 BE), m-eugenol (4 IR and −2.53 BE), p-thymol (3 IR and −2.75 BE), carvacrol (7 IR and −3.31 BE), costunolide (4 IR and −4.0 BE), cynaropicrin (5 IR and −3.06 BE), bharangin (4 IR and −4.36 BE), andrographolide (6 IR and −4.53 BE), beta-pinene (5 IR and −5.22 BE), spathulenol (6 IR and −4.98 BE), vetiverol (6 IR and - 4.96 BE), cucurbitacin B (6 IR and −5.36 BE), alpha-bisabolol (7 IR and −5.69 BE), 6-shogaol (6 IR and −3.33 BE), 6-gingerol (6 IR and −3.49 BE), beta-sitosterol (7 IR and −4.88 BE), linoleic acid (6 IR and −2.07 BE), glycyrrhizinic acid (4 HB, 2 Pi-Alkyl, 1CHB, 9 VDW and −9.5 BE), maslinic acid (4 HB, 3 Pi-Alkyl, 5 VDW and −8.5 BE), obacunone (1 HB, 1 Pi-sigma, 1 Pi-Pi T shaped, 2 Pi-Alkyl, 8 VSW and −8.1 BE), epoxyazadiradione (2 Alkyl/Pi-Alkyl, 1 Pi-Sigma, 7 VDW and −8.0 BE), azadiradionolide (3 HB, 3 Alkyl/Pi-Alkyl, 6 VDW and −8.0 BE), Ursolic acid (3 HB, 3 Pi-Alkyl, 7 VDW and −7.4 BE), gedunin (1 HB, 3 Alkyl/Pi-Alkyl, 1 Pi-Sigma, 1 CHB, 7 VDW and −7.3 BE).Lys26, Thr27, Asp30, Lys31, Asn33, His34, Glu35, Asp38, Glu37, Leu39, Phe40, Gln42, Asn90, Thr92, Val93, Gln96, Tyr127, Ser128, Glu145, Asn 149, Trp271, Arg273, Phe274, His345, Pro346, Thr347, Ala348, Trp349, Asp350, Lys353, Asp367, Lue370, Thr371, His373, His374, Glu375, Asp382, Tyr385, Ala387, Gln388, Pro389, Phe390, Arg393, Asn394, His401, Glu402, Glu406, Ser409, Gln442, Thr445, Leu503, Phe504, His505, Asn508, Arg514, Tyr515, Lys562
[[1], [87], [100]]
AlkaloidsPellitorine (5 IR and −3.4 BE), vasicine (5 IR and −6.21 BE), piperidine (9 IR and −4.31 BE), piperine (5 IR and −4.1 BE)Asp30, Lys31, Asn33, His34, Glu35, Glu37, Asp38, Phe40, Asp350, Lys353, Pro389, Phe390, Arg393, Asn394,[100]
Standards
Lopinavir (9 IR and −7.5 BE), umifenovir (7 IR and −6.5 BE), Hydroxychloroquine (10 IR and −7.1 BE)
His34, Glu37, Thr276, Asn290, Ile291, Met366, Asp367, Leu370, Gln388, Pro389, Arg393, Lys403, Glu406, Ser409, Leu410, Ala413, Lys441, Thr445, Ser494, Tyr495, Gly496, Tyr505
[10,79]
TMPRSS2 (host protease)
Class
Small molecule inhibitors
Interacting residues with different classes of phytocompounds
References
TanninsPunicalin (5 IR and −8.168 BE), punicalagin (6 IR and −7.358 BE), ellagic acid (2 IR and −6.829 BE), gallic acid (5 IR and −5.709 BE)Arg87, Ala88, Arg91, Asp92, Asn97, Asp129, Tyr401, Met404, Arg405, Gly408[79]
Steroidal lactoneWithaferin-A (2 HB, 19 IR and −5.60 BE), Withanone (1 HB; 18 HP and −4.30 BE)His296, Glu299, Tyr337, Lys342, Glu389, Asp435, Ser436, Cys437, Gln438, Asp440, Ser441, Thr459, Ser460, Trp461, Gly462, Ser463. Gly464, Cys465, Ala466, Gly472, Val473[49]
Caffeate esterCaffeic acid phenethyl ester (2 HB; 17 HP and −6.20 BE)Cys281, Val280, His296, Cys297, Glu299, Leu302, Asp435, Ser436, Cys437, Gln438, Gly439, Asp440, Ser441, Thr459, Ser460, Trp461, Gly462, Gly464, Cys465[49]
Standards
Camostat (5 IR and −7.069 BE), Camostat mesylate (1 HB and 20 HPI and -5.9 BE)
Arg87, Asn97, Phe99, Met404, Arg405, Val275, Gln276, Val278, Val 280, His296, Cys297, Leu302, Asp435, Ser436, Cys437, Gln438, Gly439, Ser441, Thr459, Trp461, Gly462, Cys465, Ala466, Gly472, Val473
[79]
[49]
Furin (host protein)
Class
Small molecule inhibitors

References
TanninsPunicalin (7 IR and −9.725 BE), punicalagin (4 IR and −9.385 BE), ellagic acid (5 IR and −7.801 BEHis194, Gly255, Pro256, Pro256, Glu257, Asp258, Asp259, Thr262, Arg298, Cys303, Asp306, Gly307, Ser311, Gly366, Ser368, Thr365, Arg 490, Trp531, Ala532,[79]
Standards
Sulcanozole (4 IR and −6.923 BE)
Val263, Phe528, Trp531, Ala532
[79]
Papain-like protease/nsp3 (viral protease)
Class
Small molecule inhibitors
Interacting residues with different classes of phytocompounds
References
Terpenoid, Flavonoid
Oleonolic acid (4 IR and −10 BE), ursolic acid (5 IR and −9.7 BE), 3β-acetoxyolean-12-en-27-ioc acid (3 IR and −9.5 BE), Isovitexin (5 IR and −9.3 BE)
His89, Trp106, Ala107, Asp108, Asn109, Val159, Gly160, Gu161, Leu162, Pro248, Tyr264
[55]
3 Chymotrypsin-like protease/nsp5 (viral protease)
Class
Small molecule inhibitors
Interacting residues with different classes of phytocompounds
References
FlavonoidEpigallocatechin (6 IR and −7.0 BE), gallocatechin (6 IR and −7.1 BE) catechin (6 IR and −7.1 BE), epicatechin (6 IR and −7.2 BE), catechin gallate (6 IR and −7.2 BE), epigallocatechin gallate (9 IR and −7.6 BE), epicatechin gallate (10 IR and −8.2 BE), gallocatechin-3-gallate (9 IR and −9.0 BE), kaempferol (4 HB, 6 HPI and −8.58 BE), quercetin (8 IR and −6.58), luteolin-7- glucoside (10 IR and −8.17 BE), myricetin (4 IR and −6.15 BE), scutellarin (2 IR and −7.13 BE), isoflavone (2 IR and −5.69 BE), Quercetin-3-O-rutinose (6 HB, 1 PS and −9.2 BE), Quercetin-7-O-glucuronide (6 HB, 1 PC, 1 PS, 1 PP, 1 Pal and −8.4 BE), quercetin-3′-O-glucuronide (6 HB, 1 PS, 2 Pal and −8.5 BE), quercetin-3-O-glucuronide (3 HB, 1 PS, 1 PC, 1 Pal and −8.5 BE), quercetin-7-O-sulfate (6 HB, 1 PS, 1 Pal and −8.4 BE), quercetin-3-O-sulfate (4 HB, 1 PS, 1 Pal and −7.6 BE), quercetin-3′-O-sulfate (6 HB, 1 PC, 3 PS and −8.1 BE), quercetin (4 HB; 1 PS, 2 Pal and −7.5 BE), kaempferol-3-O-rutinose (nicotiflorin) (4 HB, 1 PS, 1 Psi, 1 PP and −8.9 BE), kaempferol-4′-O-glucuronide (4 HB, 3 Pal and −8.0 BE), kaempferol-3-O-glucuronide (6 HB, 1 PS, 1 PP, 1 Psi and −8.3 BE), kaempferol-7-O- glucuronide (4 HB, 2 PS, 1 Psi, 2 Pal and −8.3 BE), kaempferol-7-O-sulfate (3 HB, 1 PS, 1 PP, 2 Pal and −8.3 BE), kaempferol-4′-O-sulfate (4 HB, 1 Pal and −8.2 BE), kaempferol-3-O-sulfate (3 HB, 1 PS, 1 Pal and −7.3 BE), kaempferol (1 HB, 2 PS, 2 Pal and −7.2 BE), 5,7,3′4’ - tetrahydroxy2’-(3,3- dimethylallyl) isoflavone (14 IR and −16.35 BE), myricitrin (16 IR and −15.64 BE), methyl rosmarinate (16 IR and −15.44 BE), 3,5,7,3′,4′,5′- hexahydroxy flavanone – 3 – O – beta – D glucopyranoside (13 IR and −14.42 BE), (2S)-eriodictyol 7-O-(6″-Ogalloyl)-beta-d-glucopyranoside, (15 IR and −14.41 BE), calceolarioside B (16 IR and −19.87 BE), myricetin 3-Obeta-d-glucopyranoside (17 IR and −13.70 BE); licoleafol (13 IR and −13.63 BE), amaranthin (16 IR and −12.67 BE), peonidin 3-O-glucoside (5 HB, 7 HP and −9.4 BE), kaempferol 3-O-β –rutinoside (4 HB, 6 HP and −9.3 BE), rutin (2 HB, 6 HP and −9.2 BE), 4 - (3, 4 - Dihydroxyphenyl) – 7 – methoxy - 5 - [(6 – O – b –d– xylopyranosyl – b –d- glucopyranosyl) oxy] - 2H-1-benzopyran – 2 - one (5 HB and 7 HP), quercetin-3-D-xyloside (7 HB, 5 HP and −9.1 BE), quercetin 3-O-a-l-arabinopyranoside (4 HB, 6 IR and −9.0 BE), kaempferol 3-rutinoside 40-glucoside (9 HB, 6 HP and −8.9 BE), quercetin 3-O-(6″-O-malonyl)-b-D-glucoside (3 HB, 8 HP and −8.8 BE), idaein (2 HB and 8 HP), callistephin (3 HB and 8 HP); malvin (4 HB, 8 HP and −8.7 BE), luteolin 7-rutinoside (2 HB; 9 HP; −8.6 BE), cyanin (4 HB; 4 HP; −8.5 BE), kaempferol 7-O-neohesperidoside (5HB, 7 HP and −8.4 BE), rhamnetin 3 sophoroside (5 HB, 4 HP and −8.3 BE), myricetin 3-O-b-d-galactopyranoside (5 HB, 2 HP and −8.2 BE), 2″-O-alpha-l-rhamnopyranosyl-isovitexin (3 HB, 10 HP and −8.2 BE), hesperidin methylchalcone (5 HB, 4 HP and −8.0 BE), procyanidin-B7 (4 HB, 1 HP, 1 EI and −8.2 BE), kaempferol 3-alpha-l-arabinofuranoside-7-rhamnoside (3 HB, 1 HP, 1 EI and −8.1 BE), proanthocyanidin-A2 (1 HB, 1 HP, 1 EI and −8.0 BE), 6-glucopyranosyl procyanidin B1 (5 HB, 1 HP, and −7.6 BE), pavetannin-C1 (4 HB, 1 HP, 1 EI and −7.3 BE), querceitin 3-O-robinobioside (6 HB, 8 NBI and −8.8 BE).





Lys5, Thr24, Thr25, Thr26, Leu27, His41, Cys44, Thr45, Ser46, Met49, Tyr53, Tyr54, Pro108, Lys137, Phe140, Leu141, Asn142, Gly143, Ser144, Cys145, His163, His164, Met165, Glu-166, Leu-167, Pro168, His172, Asp187, Arg188, Gln189, Thr190, Ala191, Gln192, Gly195, Asp197, Thr199, Asn238, Tyr239, His246, Leu271, Leu272, Leu286, Leu287, Glu288, Asp289.[[20], [57], [66], [67], [73], [109]]
OrganosulfurAllyl disulfide (6 IR and −15.32 BE), allyl trisulfide (4 IR and −15.02 BE), allyl (E)-1-propenyl disulfide (2 IR and −13.25 BE), allyl methyl trisulfide (4 IR and −14.36 BE), diallyl tetrasulfide (4 IR and −14.47 BE), 1,2-dithiole (T6-ACE2) (2 IR and -13.21 BE), allyl (Z)-1-propenyl disulfide (2 IR and −12.60 BE), 2-vinyl-4H-1,3-dithiine (4 IR and −14.04 BE), 3-vinyl-1,2-dithiacyclohex-4-ene (3 IR and −13.83 BE), carvone (1 IR and −12.36 BE), trisulfide, 2-propenyl propyl (5 IR and −14.36 BE), methyl allyl disulfide (3 IR and −13.56 BE), diacetonalcohol (2 IR and −13.26 BE); trisulfide, (1E)-1-propenyl 2- propenyl (2 IR and −12.00 BE); (1Z)-1-propenyl 2- propenyl (1 IR and −11.68 BE)Leu141, Asn142, Gly143, Ser144, Cys145, His163, Met165, Glu166[82]
TerpenoidsGlycyrrhizic acid (4 HB, 3 CHB, 12 VDW and −8.7 BE), 6-oxoisoiguesterin (5 IR and −9.1 BE), daturaolone (10 NBI and −7.3 BE), glycyrrhizin (7 HB; 7 NBI and −8.2 BE), calendulaglycoside B (16 IR and −8.2 BE), calenduloside (15 IR and −7.9), tenuifolin (6 HB, HP-2 and 8.8 BE), 7-Deacetyl-7-benzoylgedunin L (1 CHB, 2 HB, 10 VDW, 1 Pi-Pi T shaped, 1 alkyl, 1 Pi-alkyl, −9.1), glycyrrhizic acid (4 HB, 3 CHB, 12 VDW, −8.7), limonin: 3 HB, 1 pi-donor, 1 CHB, 4 VDW, −8.7), Obacunone (3 HB, 1 pi-donor, 1 pi-alkyl, 5 VDW, −7.5), Dihydroartemisinin (2 HB, 2A, 1 PA and −7.0 BE)Thr24, Thr25, Thr26, Leu27, His41, Cys44, Thr45, Ser46, Met49 Leu50, Tyr118, Arg131, Lys137, Phe140, Leu141, Asn142, Gly143, Ser144, Cys145, His163, His164, Met165, Glu166, Leu167, Pro168, His172, Asp187, Arg188, Gln189, Thr190, Ala191, Tyr239, Leu275, Leu286, Leu287[21,31,51,56,87]
SesquiterpeneBadrakemin acetate (2 HB, 5 HP and −8.6 BE), Samarcandin (3 HB, 2 HP and −8.5 BE)His41, Gly143, Cys145, His163, Glu166, Leu167, Pro168, Gln192[57]
Iridoid glycosideHarpagoside (3 HB, 3 HP and −6.1 BE)His41, Met49, Leu141, Asn142, Met165, Glu166[57]
Beta-diketonedemethoxycurcumin (1 IR and −7.02 BE), curcumin (2 IR and −6.04 BE); bisdemethoxycurcumin (5 IR and −7.3 BE)His41, Asn119, Phe140, Cys145, His163[73]
Beta-hydroxy ketoneZingerol (5 IR and −5.40 BE) and gingerol (5 IR and −5.38 BE)Met49, His163, Met165, Glu166, Pro168, Asp187, Arg188, Gln189, Thr190[43]
FuranocoumarinBergapten (5-methoxypsoralens) (2 IR and −5.98 BE)Phe140, His163[73]
AnthocyaninsDelphinidin 3-Sambubioside-5-Glucoside (27 IR and −12.37 BE); Delphinidin 3,3′-Di-Glucoside-5-(6-P-Coumarylglucoside) (28 IR and −11.59 BE),
2-(3,4,5-Trihydroxyphenyl)-3-[6-[(E)-3-(4-hydroxyphenyl) acryloyl]-beta-D-galactopyranosyloxy]-5,7-dihydroxy-1-benzopyrylium 2-(3,4,5- Trihydroxyphenyl)-3-[6-[(Z)-3-(4-hydroxyphenyl) acryloyl]-beta-D-galactopyranosyloxy]-5,7-dihydroxy-1-benzopyrylium (27 IR and −10.94 BE),
3-O-[b-d-Glucopyranosyl-(1->2)-[4-hydroxycinnamoyl-(->6)]-b-d-glucopyranoside](E-), 5-O-(6-O-malonyl-b-d-glucopyranoside) Pelargonidin 3-O-[b-d-Glucopyranosyl-(1->2)-[4-hydroxycinnamoyl-(->6)]-b-d-glucopyranoside](E-) 5-O-(6-O-malonyl-b-d-glucopyranoside (25 IR and −10.30 BE),
3-< [4,5-dihydroxy-6-(hydroxymethyl)-3-[(3,4,5-trihydroxy-6-< [hydroxy(4-oxocyclohexa-2,5-dien-1-ylidene)methoxy]methyl > oxan-2- yl)oxy]oxan-2-yl]oxy>-2-(3,4-dihydroxyphenyl)-7-hydroxy-5-< [3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy>-1lambda-chromen-1-ylium (25 IR and −13.59 BE), Cyanidin 3-(60 ‘-p-coumarylsambubioside) (22 and −9.58 BE), Pelargonidin 3-glucoside (4 HB, 5 HP and −8.1 BE), Cyanidin 3,5-di-O-glucoside (4 HB, 6 HP and −6.9 BE), Cyanidin 3-O-rutinoside (7 HB, 4 HP and −6.9 BE)
Thr24, Thr25, Thr26, Leu27, His41, Cys44, Met49, Leu50, Pro52, Tyr54, Gly138, Ser139, Phe140, Leu141, Asn142, Gly143, Ser144, Cys145, His163, His164, Met165, Glu166, Leu167, Pro168, Thr169, Gly170, His 172, Val186, Asp187, Arg188, Gln189, Thr190, Ala191, Gln192[27,57]
Steroidal lactoneWithanoside-II (20 IR and −11.30 BE), withanoside IV (20 IR and 11.02 BE), withanoside-V (27 IR and −8.96 BE), sitoindoside IX (24 IR and −8.37 BE), Withanolide G (4 HB, 4 HP and −8.6 BE)Thr24, Thr25, Thr26, Leu27, His41, Cys44, Thr45, Ser46, Met49, Leu50, Phe140, Leu141, Asn142, Gly143, Ser144, Cys145, His163, His164, Met165, Glu166, Leu167, Pro168, Arg188, Gln189, Thr190, Ala191, Gln192[57,84]
Alkaloid10-Hydroxyusambarensine ( 10 IR and −10.1 BE), cryptoquindoline (3 IR and −9.7 BE); 6-Oxoisoiguesterin (1 HB, 4 IR and −9.1 BE), N-[(5-methylisoxazole - 3-yl) carbonyl] alanyl-l-valyl-n1- ((1r,2z)-4-(benzyloxy) – 4 – oxo -1- [(3r)-2-oxopyrrolidin-3-yl] methyl] but-2-enyl)-l-leucinamide (3 HB, 3 HPI, −7.4 BE), 22-hydroxyhopan-3-one (1 HB, 4 IR and −8.6 BE), Chelidimerine (2 HB, 6 HP and −10.2 BE), Somniferine (3 HB, 3 HP and −8.3 BE), Adlumidine (5 HB, 2 HP and −8.2 BE), Withanone (4 HB, 3 HP and −8.2 BE), Fumariline (3 HB, 5HP and −7.8 BE), Sanguinarine (5 HB, 3 HP and −7.7 BE), Norsanguinarine (3 HB, 5 HP and −7.5 BE)His41, Met49, Tyr54, Lys137, Phe140, Leu141, Asn142, Gly143, Ser144, Cys145, Cys148, Met49, His163, Met165, Glu166, Leu167, Pro168, Asp187, Gln189, Gln192, Thr199, Tyr239, Tyr273, Leu275 Leu286, Leu287[31,57]
Tannins
Phenylpropanoids
Aromatic alcohol
Pedunculagin (5 HB, 9 NBI and −8.9 BE), punigluconin (6 HB, 12 NBI and −8.5 BE), taraxerol (11 NBI and −7.2 BE), withametelin (8 NBI and −7.9 BE), tinosporide (2 HB, 12 NBI and −8.5 BE), chebulagic acid (6 HB, 3 NBI and −6.5 BE), chebulinic acid (9 HB, 9 NBI and −8.6 BE), gallotannins (5 HB, 10 NBI and −8.3 BE), cinnamtannin-B1 (3 HB, 4 HP and −8.4 BE), barlerinoside (7 HB, 10 NBI and −7.5 BE)
Hydroxycinnamic acid (3 HB, 2A, 1 PA, and −7.5 BE)
Phenethyl alcohol (6 HB, 2 PA, −7.3 BE)
Thr24, Thr25, Thr26, His41, Cys44, Thr45, Ser46, Tyr54, Cys145, His163, Thr25, Met49, Phe140, Leu141, Asn142, Gly143, Ser144, Cys145, His164, Met165, Glu166, His172, Ala285, Asp187, Arg188, Gln189, Asp197, Thr199, Tyr239, Met276, Leu287, Leu286
His41, His164, Gln192, Thr190, Pro168, Met165,
Arg188, Arg187, Val186, Thr190, Gln192, Met49, Met165, Pro168
[[41], [56], [66]]
[51]
[51]
Standards
N3 inhibitor (native cocrystal ligand) (8 HB, 6 HPI and −7.9 BE/28 IR and −9.47 BE/23 IR and −8.12 BE), nelfinavir (9 IR and −12.20 BE); prulifloxacin (10 IR and −11.32 BE) and colistin (18 IR and −13.73 BE), x77 (4 HB, 2 PS, 1 Pal, 1 Pam, 1 PP and −8.4 BE), ribavirin (5 IR and −5.43 BE), lopinavir (3 HB, 3 HP and −9.41 BE), ritonavir (2 HB, 3 IR and −6.8 BE), l
X77 (4 HB, 2 PS, 1 PA1, 1 Pam, 1 PP and −8.4 BE)
Thr24, Thr25, Thr26, Leu27, His41, Cys44, Thr45, Ser46, Glua47, Met49, Leu50, Pro52, Tyr54, Val104, Gln110, Ile106, Asp153, Phe140, Leu141, Asn142, Gly143, Ser144, Cys145, Ser158, His163, His164, Met165, Glu166, Leu167, Pro168, Gly170, Hie172, Asp187, Arg188, Gln189, Thr190, Ala191, Gln192, Val202, Ile249, Pro293, Phe294 Val297.
[[20], [27], [31], [67], [73], [84], [109]]

RNA dependent RNA polymerase/nsp12 (viral replicase)
Class
Small molecule inhibitors
Interacting residues with different classes of phytocompounds
References
FlavonoidTheaflavin (8 HB, 2 PA and −9.1 BE), quercetin-3-O- (rutin) (9 HB, 1 Psi and −8.5 BE), quercetin-7-O-glucuronide (6 HB, 1 PA and −8.2 BE), quercetin-3′-O-glucuronide (5 HB; 1 PAm; −8.2 BE), quercetin-3-O-glucuronide (6 HB; 2 PA; 1 Pal; −8.0 BE), quercetin-7-O-sulfate (6 HB, 1 PC, 1 Pal, and −8.0 BE), quercetin-3-O-sulfate (2 HB, 2 PA and −7.1 BE), quercetin-3′-O-sulfate (6 HB, 1 PC, 1 Pal and −8.1 BE), quercetin (3 HB, 2 Psi and −7.4 BE), kaempferol-3-O-rutinose (4 HB, 2 PA and −9.2 BE), kaempferol -4′-O-glucuronide (6 HB, 1 PC and −8.3 BE), kaempferol-3-O-glucuronide (6 HB, 2 PA, 2 Pal and −7.9 BE), kaempferol-7-O-glucuronide (8 HB, 1 PC and −7.9 BE), kaempferol-7-O-sulfate (4 HB, 1 PC, 2 PA, 2 Pal and −7.3 BE), kaempferol-4′-O-sulfate (1 HB, 2 PA and −6.7 BE), kaempferol-3-O-sulfate (1 HB, 2 PA and −6.7 BE), kaempferol (2 HB, 2 Psi and −7.2 BE)Asp452, Lys545, Arg553, Ala554, Arg555, Thr556, Met615, Trp617, Asp618, Tyr619, Pro620, Lys621, Cys622, Asp623, Arg624, Thr687, Asn691, Ser759, Asp760, Asp761, Ser778, Ile779, Glu796, Lys798, Cys799, Trp800, Thr801, Glu811, Cys813, Ser814[20]
TerpenoidsGlycyrrhizic acid (7 HB, 1 CHB, 1 pi-alkyl, 16 VDW and −9.9 BE), limonin (2 HB, 2 pi-alkyl, 1 pi-pi T shaped, 10 VDW and −8.2 BE), 7-Deacetyl-7-benzoylgedunin (1 HB, 1 Alkyl/pi-alkyl, 2 CHB, 1 pi-anion, 3 pi-cation, 6 VDW and −8.2 BE), limonin glucoside (3 HB, 1 CHB, 4 Alkyl/Pi-Alkyl, 9 VDW and −8.2 BE), 7- -deacetylgedunin (1 HB, 2 CHB, 1 Pi-Alkyl, 1 Pi-sigma, 1 Pi-anion, 5 VDW and −8.1 BE), obacunone (2 HB, 1 Alkyl, 1 Pi-Anion, 8 VDW and −7.8 BE)His439, Asp452, Tyr456, Met542, Lys545, Ala547, Ile548, Ser 549, Ala550, Lys551, Arg553, Ala554, Arg555, Thr556, Val557, Ala558, Gly616, Trp617, Asp618, Tyr619, Pro620, Cys622, Asp623, Arg624, Ser682, Asp760, Asp761, Ala762, Val763, Ala797, Lys798, Trp800, His810, Glu 811, Phe812, Ser814, Arg836[87]
Standards
Remdesivir (3 IR and −6.3 BE), favipiravir (3 IR and −3.6 BE)
Lys551, Arg553, Arg555, Asp623, Ser682
[41]
Helicase/nsp13 (viral protein)
Class
Small molecule inhibitors
Interacting residues with different classes of phytocompounds
References
FlavonoidsTomentodiplacone B (9 IR and −8.4 BE), osajin (4 IR and −8.2 BE), sesquiterpene glycoside (9 IR and −8.2 BE), rhamnetin (9 IR and −8.1 BE), silydianin (6 IR and −8.1 BE)Val6, Asn9, Arg21, Arg22, Pro23, Phe24, Glu128, Arg129, Leu132, Phe133, Glu136, Arg178, Asn179, Pro234, Pro238, Ser310, Pro406, Ala407, Pro408, Asp534, Arg560[46]
Standards
Nelfinavir (6 IR and −6.2 BE), remdesivir (8 IR and −6.8 BE), prulifloxacin (7 IR and −8.1 BE)
Val6, Arg21, Arg129, Leu132, Glu136, Lys139, Glu142, Asn177, Asn179, Tyr180, Pro234, Pro238, Cys309, Met378, Asp383, Pro406, Ala407, Pro408, Arg409, Thr410, Leu412, Leu417, Arg560
[46]
Endoribonuclease/nsp15 (viral protein)
Class
Small molecule inhibitors
Interacting residues with different classes of phytocompounds
References
FlavonoidNaringin (5 IR and −7.8 BE), taxifolin (6 IR and −7.2 BE), luteolin (5 IR and −7.2 BE), apigenin (4 IR and −7.2 BE), myricetin (4 IR and −7.0 BE), wogonin (3 IR and −6.9 BE), epigallocatechin (3 IR and −6.8 BE), chlorogenic acid (6 IR and −6.8 BE), afromosin (4 IR and −6.7 BE), rutin (5 IR and −7.8 BE), silymarin (IR and −8.0 BE).His235, ASP240, Gln245, Gly248, His250, Lys290, Val292, Ser294, Val339, Glu 340, Thr341, Tyr343, Pro344, Leu346[106]
Beta-diketoneDemethoxycurcumin (5 IR and −7.51 BE), quercetin (4 IR and −6.49 BE), bisdemethoxycurcumin (1 IR and −6.56 BE), curcumin (1 IR and −6.48 BE), myricetin (4 IR and −6.52 BE), bergapten (4 IR and −5.92 BE), scutellarin (4 IR and −6.97 BE), isoflavone (2 IR and −5.47 BE)His235, Glu340, Thr341, His250, Lys290; Ser294, Gly248[73]
TerpenoidSaikosaponin-V (8 HB, 9 HP and −8.35 BE), saikosaponin-U (8 HB, 8 HP and −7.27 BE), saikosaponin-C (6 HB, 9 HP and −6.98 BE), saikosaponin-K (5 HB, 10 HP and −6.79 BE), saikosaponin-1b (4 HB, 8 HP and −6.36 BE), alpha-amyrin (1 IR and −8.1 BE), pomolic acid (2 IR and −7.9 BE), carnosol (2 IR and −7.8 BE), arjunolic acid (1 IR and −7.6), asiatic acid (5 IR and −7.4 BE), betulinic acid (1 IR and −7.3 BE), platanic acid (5 IR and −7.3 BE), alphitolic acid (1 IR and −7.2), Asiatic acid (5 IR and −7.4), ursonic acid (5 IR and −8.4 BE).Gly230, Ala232, Glu234, Hip235, Asp240, Gly245, Leu246, Gly247, Gly248, His250, Asn278, Lys290, Cys291, Val292, Cys293, Met331, Ala232, Trp333, Val339, Glu340, Thr341, Tyr343, Pro344, Leu346[[75], [106]]
CoumarinBeta sitosterol (1 IR and −8.1 BE), gliotoxin (3 IR and −6.7 BE), psoralen (5 IR and −6.7 BE), carinatine (4 IR and −6.6 BE), rhinacanthin (6 IR and −6.5 BE), caffeic acid (4 IR and −6.3 BE), coriandrin (3 IR and −6.2 BE), scopoletin (5 IR and −6.1 BE), cordycepin (4 IR and −5.6 BE), ricinoleic acid (3 IR and −5.0 BE), alpha asarone (1 IR and −4.9 BE), valproic acid (4 IR and −4.6 BE)His235, Gly248, His250, Lys290, Val292, Cys293, Ser294, Thr341, Tyr343.[106]
Organosulfurallicin (3 IR and −3.8 BE)His235, Thr341, His250[106]
AlkaloidTaspine (4 IR and −7.3 BE), ajmalicine (5 IR and −8.1 BE), reserpine (4 IR and −7.4)His235, Thr341, Gly248, His250, Lys290, Glu340[106]
SteroidsAsparoside-C (5 HB and −7.16 BE), asparoside-F (7 HB and −6.6 BE), asparoside-D (6 HB and −6.4 BE), rutin (5 HB), racemoside-A (4 HB and −5.99)Gly230, Ala232, Glu234, Hip235, Val339, Asp240, His243, Gln245, His250, Asn278, Val292, Glu340, Thr341, Leu346[16]
Standards
Hydroxychloroquine (4 IR and −5.8 BE), Nelfinavir (4 IR and −7.3 BE), ribavirin (9 IR and −5.84)
Thr26, His235, His250, Gly248, Lys290, Val-292, Ser294, Thr341, Tyr 343, Pro344,

[[73], [106]]
2′-O- methyl transferase/nsp16 (viral protein)
Class
Small molecule inhibitors
Interacting residues with different classes of phytocompounds
References
Flavonoids, Alkaloids, othersEryvarin-M (9 IR and −8.6 BE), silydianin (9 IR and −8.5), osajin (6 IR and −8.2 BE), raddeanine (8 IR and −8.2 BE)Asp6873, Asn6899, Asp6897, Amet6929, Leu6898, Asn6841, Lys6844, Cys6913, Lys6968, Phe6947, Lys6944, Asn6899, Asp6928, Cys6913, Gly6911, Leu6898, Met6929, Asp6897, Asp6928, Met6929, Cys6913, Leu6898, Gly6869, Cys6898, Asp6928, Asp6897, Asp6912, Cys6913, Leu6898, Asp6897, Gly6871, Asn6811, Met6929, Phe6947.[46]
StandardsNelfinavir (9 IR and −8.2 BE), remdesivir (9 IR and −7.0 BE), prulifloxacin (12 IR and −7.6 BE)Leu6898, Tyr6930, Gly6871, Pro6932, Lys6968, Lys6844, Gly6911, Met6929, GLy6969, Pro6932, Lys6968, Lys6844, Leu6898, Lys6996, Glu7001, Lys6844, Lys6844, Lys6968, Asp6928, Met6929, Cys6913, Asp6897, Asn6841, Gly6871, Leu6898, Phe6947, Tyr6930, Asp6897, Asn6899, Pro6932, Asp6931[46]

Note: BE - binding energy, HB - hydrogen bond, HP/HPI - hydrophobic interactions, NBI = non-bonding interactions, IR-interacting residues, EI- electrostatic interactions, CHB –carbon-hydrogen bond, VDW – van der Waals interactions. PS: π-sulfur; Pal: π-alkyl; PP: π-π; PA: π-anion; PC: π-cation; Psi: π-sigma; Pam: π-amide; Pi-H = π-hydrogen bond, PA- π-alkyl; A-alkyl.

4.2. Angiotensin-Converting Enzyme 2 (ACE2)

ACE2 is a single-pass type-1 transmembrane protein of 805 amino acids with an extracellular N-terminal peptidase domain and an intracellular C-terminus collectrin-like domain (CLD) [23]. The N- terminus has a zinc metallopeptidase binding motif (374–378 amino acids, HEMGH) essential for the interaction with SARS-CoV-2 S-protein ( Figure - 6 ). Histochemical and single-cell RNA sequencing techniques revealed that ACE2 is primarily expressed in type-II lung alveolar epithelial cells [33,95].

Fig. 6

Molecular organization of host ACE-2 monomer showing the interaction sites of different classes of phytocompounds (quinones, alkaloids, flavonoids, tannins, terpenoids, and organosulphur compounds) on the HEMGH/SARS CoV-2 spike protein binding domain and the collectrin domain (adapted from Bian and Li, 2021[118]).

A recent study, using bioinformatics, cheminformatics, and molecular docking, has demonstrated that tea flavonoids (epigallocatechin gallate, EGCG, and theaflavin gallate) have higher atomic contact energy value, dissociation constant (Ki)-value, surface area, ligand efficiency, and higher number of amino acid interactions with spike protein than synthetic hydroxychloroquine [53]). Another study showed that daturaolone, gallotannins, taraxerol, tinosporide, withanolide-A, deoxytubulosine, withametelin form strong hydrogen and non-bonding interactions with the amino acids of spike protein (between Arg 403 to Tyr 505) and have drug-likeliness properties based on Lipinski's rule of five. Moreover, these bioactive compounds have lower toxic effects and better gastrointestinal absorption than standards [56]. A simulation study using the crystal structure of SARS-CoV-2 S protein demonstrated that saikosaponin-U and saikosaponin-V, oleanane derivatives found in Chinese medicinal plants, can also interact with the spike glycoprotein via their octadecahydropicene and oxane rings [75]. Using molecular docking and conceptual density functional theory approaches, Kulkarni et al. showed that components of essential oils (monoterpenes, terpenoid phenols and phenyl propanoids) have the potential to interact with the RBD [47]. The phytocompounds punicalagin and punicalin (from Pomegranate), tenufolin, cinnamtannin-B1, pavetannin-C1, 6-glucopyranosyl procyanidin B1, procyanidin-B7, proanthocyanidin-A2 and Kaempferol-3-alpha-l-arabinoside-7-rhamnoside (from Cinnamon), frieldlin, and stigmasterol (from Clerodendrum spp) were also found to be effective candidates exhibiting important interactions with the targeted S protein [41,66,79], suggesting that they could serve as possible candidates for further in-vitro and in-vivo evaluations. Additionally, a molecular dynamics simulation study of the complex of RBD of S-protein with taraxerol for a time scale of 40 ns revealed its potent anti-SARS-CoV-2 activity [41]. Tellimagrandin-II and O-demethyl-deoxy curcumin isolated from plants used in Indian traditional medicine demonstrated stable intramolecular interactions with Asn343, which could be an important hit to affect host-immune evasion by inhibiting S-protein glycosylation [85].

The complex between viral S protein and human ACE2 has also been explored to identify antiviral phytochemicals. Using molecular dynamics, hesperidin, a major flavonoid present in citrus fruits, has been demonstrated to interact with this complex noncompetitively at a site different from that of S-protein. Further, the antiviral activity of hesperidin was validated by a quantitative structure-activity relationship study [12]. Another study, using virtual screening followed by protein-ligand interaction approach, showed that phytochemicals like glycyrrhizinic acid, maslinic acid, ursolic acid, corosolic acid, 2-hydroxyseneganolide, gedunin, and oleanane can bind firmly with the active site and other important amino residues of S protein and ACE2 through multiple noncovalent interactions [87]. Of particular interest, His-34 is an important amino acid of ACE2 receptor as it lies on the surface and exhibits crucial interactions with the S protein. One of the molecular dynamic studies revealed that the andrographolide and pterostilbene could negatively affect SARS-CoV-2 by interacting with the His-34 [10]. Rilapladib, a quinoline, can interrupt the spike-ACE2 complex [11]. Natural compounds such as isothymol, thymol, p-cymene, limonene, and gamma-terpinene (from Ammoides verticillata), and 17- organosulfur compounds (from garlic) were also found to be potential inhibitors of ACE2 receptor [1,82]. Further, xanthones, proanthocyanidins, secoiridoids, naringenin, hesperetin, baicalin and neohesperidin, scutellarin, nicotinamin, and glycyrinodin could exhibit ACE2 inhibition activity [58]. Hesperidin can modulate the binding energy of ACE2-spike protein complex and affects the stability of viral-host interaction [12]. At the binding contact of the spike-ACE2 complex, the di-hydroflavone moiety of hesperidin has been predicted to be parallel to the β-6 sheet of RBD [92]. Apart from this, punicalin and punicalagin from pomegranate peel are predicted to interact with ACE2 and block entry of SARS-CoV-2 into host cells [79]. Several bioactive compounds shown in research article by Mondal et al can interact with hot-spot binding residues (Lys31 and Lys353) of the ACE2 receptor through hydrogen bond or non-bonded interactions [56]. Besides these, geranium and lemon essential oils downregulate the expression of ACE2 in human colon adenocarcinoma cells as observed by western blot experiments [48]. More details of in-silico studies, including types of interactions, binding energy values, as well as identity and position of interacting amino acids with different phytocompounds are presented in Table-1.

4.3. Transmembrane Serine Protease-2

Human TMPRSS2 is a 492 amino acid type-II transmembrane protein that belongs to the serine protease family. The N-terminal half consists of a predicted transmembrane domain (84–106 amino acids), a low-density lipoprotein receptor class A domain (LDLRA, 113–148 amino acids), and a scavenger receptor cysteine-rich domain (SRCR, 149–242 amino acids), whereas the C-terminus half contains a serine protease domain (255–492 amino acids) [63] ( Figure-7). For priming of the viral spike protein, TMPRSS2 cleaves off the spike protein at two sites, Arg-685/Ser-686 and Arg-815/Ser-816. The catalytic site of TMPRSS2 consists of amino acid residues Ser-441, His-296, and Asp-345, whereas the substrate-binding sites include Asp-435, Ser-460, and Gly-462 [34]. Molecular docking studies showed that the bioactive constituents of different plants enlisted under the TMPRSS2 section in Table-1 and presented in Figure-7 display significant interactions with the amino acid residues of the serine protease domain (255–492), particularly with the amino acids of catalytic and substrate binding sites.

Fig. 7

Molecular structure of transmembrane protease serine-2 (TMPRSS2) and the interaction sites of tannins, steroidal lactone, and caffeate ester in its domains. H-296, D-345 and S-441 are the catalytic residues present in the serine protease domain (adapted from Paoloni-Giacobino et al, 1997 [63] and Mahmoud and Jarrar, 2021[119])

The phytocompounds withaferin-A, withanolide-N, punicalin, punicalagin, ellagic acid and gallic acid could interact well with the important amino acid residues of TMPRSS2 [49,79]. Withanolide-N not only showed stronger interactions compared to withaferin-A, but it could also downregulate the expression of TMPRSS2 mRNA in human breast cancer cell line. This observation led authors to predict its dual role in inhibiting SARS-CoV-2 entry. The disruption of substrate binding was most likely due to interactions of withanolide-N with the Ser-441 [49].

4.4. Furin

Furin is a subtilisin-like proprotein convertase located in the trans-Golgi network. It cleaves a precursor protein with a specific amino acid pattern (Arg-X-X-Arg). The furin-like cleavage site, a 12-nt insertion at S1/S2 junction in the spike coding sequence, is absent in other members of the same clade [13,19]. Furin cleavage site enhances receptor affinity and facilitates membrane fusion. The cleavage of this site occurs via priming of S protein which could provide a gain-of-function benefit to the SARS-CoV-2 for an efficient human to human transmission compared to other members of beta coronaviruses [13,19,54]. In-silico analyses suggested that punicalagin, punicalin, ellagic acid and gallic acid from pomegranate could interact with the active site residues and other crucial amino acid residues of furin (Table-1) and form more stable complexes than sulconazole (control) [80]).

5. SARS CoV-2 replication inhibitors

The replication and transcription of the SARS-CoV-2 RNA genome (~ 30 kb) is catalyzed by an RNA-dependent RNA polymerase (RdRp) domain located at the C-terminus of non-structural protein 12 (nsp12) in association with other non-structural proteins such as nsp3 (papain-like protease), nsp5 (3-chymotrypsin-like protease), nsp15 (endoribonuclease) and nsp16 (2-O’ MTase).

5.1. Papain-like protease (PLpro)/nsp3

Papain-like protease (PLpro)/nsp3 is a multidomain transmembrane protein with an active site containing catalytic triad residues (Cys-111, His-272 and Asp-286) in between thumb and palm protein domains ( Figure-8 ). This protein is autocleaved from nsp3 protein via its intrinsic proteolytic activity. PLpro can also perform deISGylation of host proteins which could lead to inhibition of host innate immune response [18,40]. Due to its key role in viral replication and disease pathogenesis, it represents a promising drug target [52]. The docking score and the prediction of the molecular interactions showed that phytochemicals oleanolic acid, 3β-acetoxyolean-12-en-27-oic, and isovitexin could efficiently interact with the PLpro mainly by hydrogen bond [55]. Another study showed that catechins from green tea can interact to the S1 ubiquitin-binding site of PLpro which might lead to inhibition of its protease enzymatic function as well as abrogation of SARS-CoV-2 inhibitory role on interferon-stimulated gene system [18]( Table 1 ).

Fig. 8

Location of amino acid interaction site (89–264) of tannins and flavonoids on SARS-CoV-2 nsp3 papain-like protease monomer(adapted from Joshi et al., 2020 [40]).

5.2. 3-chymotrypsin-like protease (3-CL pro)/nsp5

The 3CLpro, also called as viral main protease (or nsp5), consists of N-terminal finger domain (1–9 amino acids), domain-1 (10–99 amino acids), domain-2 (100–182 amino acids) and the C-terminal domain-3 (amino acid residues 198–303) [40,94]. The catalytic dyad consists of His-41 and Cys-145 (Fig. 9 ). The dimerization of 3-CLpro is required for its proteolytic activity.

Fig. 9

The interaction sites of several classes of phytocompounds on different domains of SARS-CoV-2 3-chymotrypsin like protease (3CLpro) including the catalytic dyad residues (His-41 and Cys-145; shown in purple). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) (3CLpro domain organization is adapted from Joshi et al., 2020 [40])

In-silico screening followed by molecular docking analyses suggested that the phytochemicals bisdemethoxycurcumin, scutellarin, desmethoxycurcumin, quercetin, myricetin, luteolin and mundulinol could potentially inhibit 3-CL pro as these compounds exhibit low binding energy [25,73]. Another study recommended certain compounds such as catechin, naringenin, kaempferol, glucosides, quercetin, and epicatechin-gallate as potential inhibitors of 3CLpro [43]. The phytocompounds like melitric acid-A, salvianolic acid-A, withanoside-V, and a few bioactive compounds from Calendula officinalis showed higher binding affinities with 3-CLpro than the N3 and lopinavir (standards). Also, they could have important interactions with the amino acid residues of the catalytic dyad [20,21,24,56,84]. In another study, a database of medicinal plants consisting of more than 30,000 potential anti-viral phytochemicals was screened, and the top hits that could inhibit SARS-CoV-2 3CLpro function and viral RNA replication were selected. These hits include myricitrin, 5,7,3′,4′-tetrahydroxy2’-(3,3- dimethylallyl) isoflavone, methyl rosmarinate, (2S)-eriodictyol 7-O-(6″-O-galloyl)-beta-d-glucopyranoside, calceolarioside B, 3,5,7,3′,4′,5′-hexahydroxy flavanone-3-O-beta-d-glucopyranoside, myricetin 3-O-beta-d-glucopyranoside, licoleafol, amaranthine, colistin, nelfinavir, and prulifloxacin [67]. Terpenoids (6-Oxoisoiguesterin and 22-hydroxyhopan-3-one) and some anthocyanin derivatives could stably interact with catalytic dyad and other crucial residues via hydrogen and hydrophobic interactions [27,31].Epigallocatechin, gallocatechin, and epicatechin from green tea also showed the potential to restrict the activity of 3-CL pro (Ghosh et al., 2020[101]). Similarly, several phytocompounds bind firmly at the catalytic dyad (Cys-145 and His-41) and other crucial amino acid residues (Phe-140, Leu-141, Asn-142, Gly-143, Ser-144, Glu-166, His-163, His-164, Met-165, Leu-167, Pro-168, His-172, Asp-187, Arg-188) of 3-CL pro via making hydrogen bonds, hydrophobic bonds and other interactions (like Pi-alkyl and Pi-Pi T-shaped, van der Waals etc). Phytocompounds extracted from Avincennia officinalis and Iranian medicinal plants have also been proposed as inhibitors of 3-CLpro [51,57]. Tanshinones, a class of natural phytocompounds have been found to inhibit 3-CLpro activity of SARS-CoV in-vitro enzymatic assay studies (Park et al., 2012[115]). Likewise, as listed in Table-1 and shown in Figure-9, several phytocompounds have ability to block 3-CLpro preferentially by interacting with its domain-1 and domain-2.

5.3. RNA dependent RNA polymerase/nsp12

With the help of accessory subunits nsp7 and nsp8, the catalytic subunit nsp12 of RdRp plays a crucial role in the transcription cycle of SARS-CoV-2 [88]. Its structure is highly similar to SARS-CoV. The nucleotide triphosphate (NTP) entry channel comprises positively charged amino acid residues Lys-545, Arg-553, and Arg-555. The right hand-like structure of the RdRp domain is further divided into a finger-domain (398–581 and 628–687 amino acids), a palm-domain (582–627 amino acids and 688–815 amino acids), and a thumb domain (816–919 amino acids). Two Zn ions are also required to stabilize three-dimensional structure of the RdRp [3,45] ( Figure-10 ). Tyr-618, Asn-691, Met-755, Ile-756, Leu-757, Ser-759, Asp-760, Asp-761, Val-763, Phe-812, Cys-813 and Ser-814 are some of the amino acids residues that are crucial in interacting with the nsp7/8 complex. In addition, Asp-761 and Asp-762 are active site residues [3].

Fig. 10

Molecular structure of SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and the interaction sites of flavonoids and and terpenoids on its different domains(protein domain organization is adapted from Zhang et al., 2020[120])

Several compounds have been analyzed in-silico against these important sites to investigate their possible antiviral viral targets for the SARS-CoV-2. Green tea polyphenols EGCG and theaflavin gallates including theaflavin-3-O-gallate (TF2a), theaflavin-3′-digallate (TF2b) and theaflavin 3,3′-digallate (TF3) have the ability to form stable bound conformations with the RdRp protein and could interact with the catalytic site indicating their potential to serve as inhibitors [81].

Several alkaloids from Argemone mexicana and Clerodendrum spp. could be a potential inhibitory candidates against the SARS-CoV-2 RdRp protein [41,62] ( Table-1 ).

5.4. RNA helicase (nsp13)

It is a multi-functional magnesium ion-dependent protein that belongs to the helicase superfamily-1 (SF-1) and has 5′ to 3’ based RNA and DNA unwinding activities [121]. Compounds such as tomentodiplacone-B, sesquiterpene glycoside, rhamnetin, osajin, and silydianin have been shown to exhibit better docking results than those of remdesivir, nelfinavir, and prulifloxacin (standards) [46] ( Table-1 ).

5.5. Endoribonuclease/nsp15

Endoribonuclease/nsp15 cleaves RNA genome into multiple subgenomic RNAs (sgRNAs). Based on the docking score, phytocompounds asparoside-C, asparoside-D, asparoside-F, racemoside-A, and rutin (from Asparagus racemosus) were found to be effective against nsp15 endoribonuclease [16]. The 100 nano-second based molecular dynamic simulation study and molecular mechanics-generalized born solvent accessibility calculations demonstrated that some phytoconstituents such as withanolide-N, ashwagandanolide, withanoside-X, and dihydrowithaferin-A from Withania somnifera could potentially suppress the nsp15 endoribonuclease activity of SARS-CoV-2 [17]. Another study revealed the binding capacity of silymarin, sarsasapogenin, ursonic acid, rosmarinic acid, curcumin, ajmalicine, novobiocin, aranotin, gingerol, and alpha terpinyl acetate to nsp15 protein [106].

5.6. 2′-O-methyltransferase (2′-O-MTase)/nsp16

This is a highly conserved protein of coronaviruses. It is known to play an essential role in viral replication and evasion of host cell innate immunity [64]. Phytocompounds like eryvarin-M, osajin, raddeanine, and silydianin have been found to exhibit the best docking results [46] ( Table-1 ).

6. SARS-CoV-2 assembly inhibitors

Structural proteins, membrane, envelope and nucleocapsid, play essential roles in the assembly and formation of the infectious virion particles. Therefore, targeting these proteins could be a promising approach to inhibit virus multiplication and transmission.

6.1. Envelope protein

E protein (8–12 kDa) is involved in host cell binding, penetration, virion assembly, and budding. It is a transmembrane ion channel protein with an N-terminal ectodomain and an endodomain at C-terminus. Structural insights revealed that compounds from Withania somnifera could block the ion channel activity of E protein by binding to the pore region [5].

6.2. Nucleocapsid protein

N protein is a 419 amino acid protein with conserved N-terminal domain (NTD), Serine/Arginine rich motif (SR) domain, central linker region, and a C-terminal domain (CTD). It plays an essential role in viral genome packaging and efficient replication. The N protein is highly immunogenic and is produced in high amounts during infection [22,96].

An in-silico screening study revealed emodin, anthrarufin, alizarine, aloe-emodin, and dantron as phytocompounds with good binding affinity with the N-terminal domain of N protein. ADMET prediction revealed that anthrarufin, emodin, aloe-emodin, alizarine, and dantron could be potential candidate drugs to treat COVID-19 [69].

7. In vitro and in vivo anti-SARS-CoV-2 activities of plant-derived compounds

Plant-based polyphenols (such as phenolic acids, anthocyanins, lignans, flavonoids, and stilbenes) and carotenoids (such as xanthophylls and carotenes) are being used to generate antivirals against various coronaviruses. Recent data on plant-derived compounds showed their potent and significant SARS-CoV-2 inhibition activity in-vitro and in-vivo. A comprehensive study, conducted by Jia-Tsrong Jan et al., screened 190 supplements as well as traditional medicines from Chinese herbs to identify the SARS-CoV-2 infection inhibitors in-vitro in Vero-E6 cells. in-vitro enzymatic assays were coupled with in-silico modelling to confirm the antiviral activity against SARS-CoV-2 protease and RNA-dependent-RNA-polymerase (Jan et al., 2021). Further, the efficacy of these promising compounds was tested in a hamster challenge model. This study identified the anti-SARS-CoV-2 activity in nelfinavir, Perilla frutescens, mefloquine, and Mentha haplocalyx [38]. This observation is very encouraging and warrants an urgent need for testing several other potent phytocompounds in small animal models to speed up the process of developing COVID-19 therapeutics.

A wide range of natural compounds has been proposed to be used in treating COVID-19(either alone or in combination with FDA-approved drugs) including ginkgolic acid, shiraiachrome A, resveratrol, and baicalein. Moreover, ginkgolic acid is a specific covalent inhibitor of SARS-CoV-2 cysteine proteases, targeting PLpro and 3-CLpro in-vitro [93]; and [15] (please refer Table 2, Table 3 for antiviral and immunomodulatory functions of small molecule inhibitors ).

Table 2

Effect of phytocompounds on targeted SARS-CoV-2 proteins/replication/infection in cell-free and cell-based studies.

Sl no
Crude extract/compound
Virus/RNA/enzyme inhibition/cytotoxicity
Inhibitory assay
Dosage (IC50/EC50/CC50)
References
Flavonoid
01Baicalein3CLpro -InvitroIC500.39 ± 0.11 μM[50]
SARS-CoV-2 replicationVero cellsEC502.92 ± 0.06 μM[50]
CytotoxicityVero cellsCC50>500 μM[50]
02Baicalin3CLproIn-vitroIC5083.4 ± 0.9 μM[50]
03Scutellarein3CLproIn-vitroIC505.80 ± 0.22 μM[50]
04Dihydromyricetin3CLproIn-vitroIC501.20 ± 0.09 μM[50]
05Quercetagetin3CLproIn-vitroIC501.24 ± 0.14 μM[50]
06Myricetin3CLproIn-vitroIC502.86 ± 0.23 μM[50]
07Baicalin3CLpro (FRET)In-vitroIC506.41 ± 0.95 μM[78]
Replication inhibitionVero E6EC5027.87 ± 12.95 μM[78]
CytotoxicityVero E6CC50>200 μM[78]
08Baicalein3CLpro (FRET)In-vitroIC500.94 ± 0.20 μM[78]
ReplicationVero E6EC502.94 ± 1.19 μM[78]
CytotoxicityVero E6CC50>200 μM[78]
09Theaflavin3CLpro (FRET)In-vitroIC508.44 μg/mL[39]
CytotoxicityHEK293TCC50>40 μg/mL[39]
10Myricetin3CLpro (FRET)In-vitroIC500.2 μM[107]
11Baicalin3CLpro (FRET)In-vitroIC5034.71 μM[103]
12Herbacetin3CLpro (FRET)In-vitroIC5053.90 μM[103]
13Pectolinarin3CLpro (FRET)In-vitroIC5051.64 μM[103]
Terpenoids
14Glycycrrhizin (triterpenoid saponin)3CLproIn-vitroIC5030 μM (0.024 mg/mL)[86]
Virus titer titVero cellsTCID500.44 mg/mL[86]
CytotoxicityVero cells4 mg/mL (no cytotoxicity)[86]
15Δ9-Tetrahydro cannabinolAntiviral activityVero cellsEC5013.17 μM[97]
CytotoxicityVero cellsCC5029.34 μM[97]
16Δ9 -THCAntiviral activityVero cellsEC5010.25 μM[97]
CytotoxicityVero cellsCC5025.79 μM[97]
17CBNAntiviral activityVero cellsEC5011.07 μM[97]
CytotoxicityVero cellsCC5019.9 μM[97]
18CBDAntiviral activityVero cellsEC507.91 μM[97]
CytotoxicityVero cellsCC5016.72 μM[97]
19CBDAAntiviral activityVero cellsEC5037.61 μM[97]
CytotoxicityVero cellsCC5059.53 μM[97]
20AndrographolideSARS-CoV2 infection in-vitroVero E6EC506.58 μM[42]
Plaque reductionVero E6EC500.28 μM
CytotoxicityCC5027.77 μM
21AndrographolidePlaque reductionCalu-3 cellsEC500.034 (μM)[72]
Cytotoxicitya) HepG2
b) imHC
c) HK-2
d) Caco-2
e) Calu-3
f) SH-SY5Y
CC50
CC5
CC5
CC5
CC5
CC5
a) 81.52 μM
b) 44.55 μM
c) 34.11 μM
d) 52.30 μM
e) 58.03 μM
f) 13.19 μM
22Arteether (sesquiterpene lactone)SARS-CoV-2 infectionVero E6EC5031.86 ± 4.72 μM[14]
CytotoxicityVero E6CC50>200 μM[14]
23Artemether (sesquiterpene lactone)SARS-CoV-2 infectionVero E6EC5073.80 ± 26.91 μM[14]
CytotoxicityVero E6CC50>200 μM[14]
24Artemisic acid (sesquiterpene lactone)SARS-CoV-2 infectionVero E6EC50>100 μM[14]
CytotoxicityVero E6CC50>200 μM[14]
25Artemisinin (sesquiterpene lactone)SARS-CoV-2 infectionVero E6EC5064.45 ± 2.58 μM[14]
CytotoxicityVero E6CC50>200 μM[14]
26Artemisone (sesquiterpene lactone)SARS-CoV-2 infectionVero E6EC5049.64 ± 1.85 μM[14]
CytotoxicityVero E6CC50>200 μM[14]
27Dihydroartemisinin (sesquiterpene lactone)SARS-CoV-2 infectionVero E6EC5013.31 ± 1.24 μM[14]
CytotoxicityVero E6CC5031.44 ± 0.73 μM[14]
28Artesunate (sesquiterpene lactone)SARS-CoV-2 infectionVero E6EC5012.98 ± 5.30 μM[14]
CytotoxicityVero E6CC5055.08 ± 2.32 μM[14]
29Arteannuin (sesquiterpene lactone)SARS-CoV-2 infectionVero E6EC5010.28 ± 1.12 μM[14]
CytotoxicityVero E6CC5071.13 ± 2.50 μM[14]
30CannabidinolSARS-CoV-2 infectionVero E6CC5071.13 ± 2.50 μM
1.25 μM (SARS CoV2γ)
0.85 μM (SARS CoV2α)
0.86 μM (SARS CoV2β)
0.63 μM (SARS CoV2)
[14]
[61]
CytotoxicityA549-ACE2EC50
Tannins
31PunicalinRBD-ACE2 binding assay (ELISA)InvitroIC500.14 mg/mL[80]
32
33
34
35
36
37
38
Corilagin
Corilagin
Corilagin (RAI-S-37)
Corilagin (RAI-S-37) + Remidesivir
Corilagin (RAI-S-37)
Corilagin (RAI-S-37)
Corilagin (RAI-S-37)
SARS-CoV-2 inhibition
RBD-ACE2 binding assay (ELISA)
Cytotoxicity
Cytotoxicity
Cytotoxicity
SARS-CoV-2 RdRp inhibition
SARS-CoV-2 RdRp inhibition
SARS-CoV-2 RdRp inhibition
SARS-CoV-2 RdRp inhibition
SARS-CoV-2 infection
Vero
In-vitro
HEK293 cell
LO2 cells
Beas-2B cell
HEK293 cell transfected with nsp7 + nsp8 + nsp12
HEK293 transfected with nsp7 + nsp8 + nsp12
HEK293 transfected with nsp7 + nsp8+nsp12/nsp10+nsp14
HEK293 transfected with nsp7 + nsp8+nsp12/nsp10+nsp14
Vero cells
EC50
IC50
CC50
CC50
CC50
EC50
EC50
EC50
EC50
EC50
0.13 μmol/L
24.9 μM
>100
>100
>100
3.33 ± 0.52 μmol/L
1.25 ± 0.52 μmol/L
3.65 ± 0.56 μmol/L
1.84 ± 0.27 μmol/L
0.13 μmol/L
[108]
[93]
[93]

[108]
[108]
[108]
[108]
39EGCG3CLpro (FRET)In-vitroIC507.58 μg/mL[39]
CytotoxicityHEK293TCC50>40 μg/mL
Others
40Cepharanthine (alkaloid)SARS-CoV2 infectionVero cellsEC502.8 μM[38]
CC5012.9 μM
41Emetine (alkaloid)SARS-CoV2 infectionVero cellsEC500.000397 μM[38]
CC501.53 e + 6 μM
426-Gingerol (beta-hydroxy ketone)SARS-CoV2 infectionVero E6EC50>100 μM[42]
CytotxicityVero E6CC50>100 μM
43Panduratin A (Diarylheptanoid)SARS-CoV2 post infectionVero E6EC500.81 μM[42]
Vero E6CC5014.71 μM
SARS-CoV2 pre-entryVero E6EC505.30 μM
Vero E6CC5043.47 μM
Plaque reductionVero E6EC500.078 μM
SARS-CoV2 infectionCalu3EC502.04 μM
CytotoxicityCalu3CC5043.92 μM
Plaque reductionCalu3EC500.53 μM
44Emetine hydrochloride (alkaloid)SARS-CoV-2 virus reductionVero E6EC500.46 μM[111]
CPE inhibitionVero E6EC501.5625 μM[111]
CytotoxicityVero E6CC5056.46 μM[111]
45Phillyrin (KD-1)
Lignan)
Anti-HCoV-229EVero E6EC5064.53 μg/ml[113]
Cytopathic effectVero E6EC5063.90 μg/ml[113]
CytotoxicityVero E6CC501959 μg/ml[113]
Huh7CC501034 μg/ml[113]
Reduce the production of proinflammatory cytokinesVero E6–CPE (cytopathic effect)(250, 125, and 62.5 μg/ml of KD1) TNF-α, IL-6, IL-1β, MCP-1, and IP-10) at the mRNA levels.[113]
46

47
Cepharanthine (bisbenzylisoquinoline alkaloid)
Lycorine (alkaloid)
SARS-CoV-2 RNAVeroE6/TMPRSS2EC500.35 μM,[114]
Cytotoxicity
SARS-CoV-2 infection
VeroE6/TMPRSS2
Vero cells
CC50
EC50
25.1 μM
0.878 μM
[114]
[112]
48Digoxin (cardiotonic glycoside)SARS-CoV-2 infectionVero cellsEC500.043 μM[110]
CytotoxicityVero cellsCC50>10 μM[110]
49

50
51
52
Ouabain (Cardiac glycoside similar to digitoxin)
Herbacetin
Pectolinarin
Rhoifolin
SARS-CoV-2 infectionVero cellsEC500.024 μM[110]
Cytotoxicity
3CLpro (FRET)
3Clpro (FRET)
3CLLpro (FRET)
Vero cells

in-vitro
in-vitro in-vitro
CC50
IC50
IC50
IC50
>10 μM
33.17 μM
27.45 μM
37.78 μM
[110]
[71]
Crude extracts
53Andrographis paniculata extractSARS-CoV2 infectionVero E6EC5068.06 μg/ml[42]
CytotoxicityCC50>100 μg/ml
54Andrographis paniculata extractPlaque assayCalu-3 cellsEC500.036 (μg/mL)[72]
55Zingiber officinale rhizome extractInhibition of SARS-CoV2 infectionVero E6EC5029.19 μg/ml[42]
CytotoxicityVero cellsCC5052.75 μg/ml
Plaque reductionVero cellsEC501.45 μg/ml
56Boesenbergia rotunda (extract)SARS-CoV2 infectionVero cellsEC503.62 μg/mL[42]
Vero cellsCC5028.06 μg/mL
57
58
Scutellaria baicalensis extract
Pomegranate peel extract
3CLpro assayIn-vitroIC508.52 ± 0.54 μg/mL[50]
SARS CoV2 RNA replicationVero cellsEC500.74 ± 0.36 μg/mL[50]
Cytotoxicity
RBD-ACE2 binding assay (ELISA)
Vero cells
In-vitro
CC50
IC50
>500 μg/mL
0.06 mg/mL

[80]

Table 3

Effect of small molecule inhibitors on host factors as well as on different cytokines (immunomodulatory functions)

Sl noCompound/plantPropertiesBiological/immune-actionStudies in In-vivo modelsReferences
01QuercetinImpacts on ACE2 and Furina) Gene silencing
b) Expression studies
c) Transgenic mouse models
Quercetin affected ACE2 expression. In addition, it was found that it could alter the expression of 98 of 332 (30%) genes which encode human proteins that serve as target for the SARS-CoV-2[29]
02citral and lemon grassanti-inflammatory actionInhibits IL-6, IL-10, TNF-α, IL-4, IFN[Upsilon] and IL-1β, either release or production and NLRP3 inflammasome activation via blocking activites of proteins, NF-kB,p65, ATP-induced caspase-1In macrophages challenges with LPS-induced mouse ASLN model[[98], [104]]
03Ginsenosideanti-inflammatory actionDown-regulates IL-6, TNF-α, mRNA expression via blocking the activation of NF-kBII/R induced lung injury in-vivo[102]
04Withaferin-AImmunosuppressantAffect the release of TNF-α, IL-1α, IL-1β, IL-5, IL-3, IL-6, IL-8, IP-10, CCL2, MCP-1, SDF-1α, MIP-1α, MIP-1β and GM-CSF.ATP-stimulated monocyte-derived THP-1 cells. Also mouse and human islet cells – in vitro.[77,99]
05Kaempferolanti-inflammatory actionTNF-α, IL-1β, IL-6, IL-8 via inhibiting the activation of PKC θhuman mast cells[105]

06




EGCG




Regulation of cytokine driven signaling pathways

Downregulating the IL-6 and IL-6 driven JAK-STAT pathway
Similarly by affecting IL-1 driven MAPK pathway
Reduced the protein levels of the receptors including CD11a, CXCR3, and CCR2 in human T-lymphocyte cells




Primary human melanocytes, human T cells or purified CD8+ T cells from PBMC



[18,60]



Prevents the cytokine storm and mucous hypersecretion in COVID-19[81]
07Cannabidolanti-inflammatory and immunosuppressiveThese effects are mediated by inhibition of pro-inflammatory cytokine release (e.g. tumor necrosis factor-a, Interferon-gamma, IL-1b, IL-6, and IL-17) and stimulation of several anti-inflammatory cytokine production (e.g. IL-4, IL-5, IL-10, and IL-13).COVID 19 Patientshttps://clinicaltrials.gov/ct2/show/NCT04731116
08FTHCOnly low anti-inflammatory activityEpithelial cancer cell lines (A549)[6]
09FCBDshowed reduction of IL-6 and IL-8 secretion levels from lung epithelial cells with an IC50 values of 3.45 and 3.49 μg/mL respectively.Epithelial cancer cell lines (A549)[6]

In another study, 122 Thai natural products for anti-SARS-CoV-2 activity were screened using fluorescence-based nucleoprotein detection combined with viral plaque reduction assay. This work showed that the extract of Boesenbergia rotunda and its phytochemical compound, panduratin A reduce SARS-CoV-2 infectivity in Vero E6 cells at pre-entry and post-infection phases [42]. Artemisinin B, an antimalarial drug derived from Chinese herbs, also showed anti-SARS-CoV-2 in these cells by blocking SARS-CoV-2 at the post-entry level [14].

Anti-SARS-CoV-2 activity evaluation of Andrographis paniculata extract and Andrographolide in human lung epithelial-carcinoma cell-line (Calu-3) using a high-content imaging platform in combination with plaque reduction assay showed potent inhibition of SARS-CoV-2 infection with minimal cytotoxicity [72]).

In another study, Glycyrrhizin showed potential antiviral activity against SARS-CoV-2 by inhibiting the viral 3-CL pro that is essential for viral replication [86]. Similarly, several other plant-derived compounds including tea polyphenols EGCG, theaflavin, baicalein, and shuanghuanglian inhibit 3-CLpro activity and the viral replication in Vero E6 cell line [39,50,78]. Overall, the potent antiviral and anti-inflammatory activities of plant-derived compounds further warrants need of developing phytochemical-based SARS-CoV-2 treatment options.

7.1. Clinical evaluation of plant-based therapeutics

In-depth systemic randomized and non-randomized ongoing clinical trials of single plant species (Tinospora cordifolia, Nigella sativa, Boswellia serrata, Acai Palm Berry, Caesalpinia spinosa, Cinchona/Stevia, Cannabis sp, Brazilian Green Propolis), plant-based bioactive compounds (EGCG, quercetin, silymarin, hesperidin, escin, colchicine, resveratrol, cannabidiol, melatonin etc.), as well as poly-herbal formulations (ArtemiC, Drug – ADAPT-232, Dietary supplement: Inflammation-I, Inflammation-II, Inflammation-III, Tomeka, Shanshamani Vati Plus, Dietary Supplement: QuadraMune (TM), Ayurvedic formulation, Dietary Supplement: Cretan IAMA, Individualized-Chinese herbal medicine) showed their potential to interfere with COVID-19 pathogenesis via inhibiting virus replication, virus-mediated pneumonia as well as inmmune dysregulation such as cytokine storming ( Supplementary Table ). Certain anti-inflammatory herbal medicines from Andrographis paniculata, Citrus spp, and Cuminum cyminum can relieve fever and cough in COVID-19 patients [37]). Few other medicinal plants such as Glycyrrhiza glabra, Thymus vulgaris, Allium sativum, Althea officinalis, Panax ginseng and constituents of Camellia sinensis may modulate the immune system and provide supportive therapy against COVID-19 via upregulating levels of interleukins (IL-1α, IL-1β), monocytes, and lymphocytes in patients [4,37]. Apart from these, green tea polyphenols can prevent airway blockage by reducing mucin hypersecretion, a phenomenon seen in COVID-19 patients [81]. Moreover, several plant species act as good source of expectorants as they can elevate the water contents of respiratory mucus or diluent of mucus and thus also contributing towards prohibiting airway blockage [26,44].

8. Conclusions

Since December 2019, SARS-CoV-2 infection and transmission have been a huge concern worldwide. Currently available therapies inhibit SARS-CoV-2, however, they could be associated with severe side effects as well as drug-nutrition interactions which could be harmful to severely infected patients.

On other hand, the complementary approach including plant-derived compounds could be used in controlling COVID-19 in the future. Our review herein presented a compilation of in-silico, in-vitro,cell culture , and in-vivo studies on numerous plants, plant formulations, and their bioactive constituents that may block the life cycle of SARS-CoV-2 in all possible ways. Beyond the antiviral functions, plant-derived therapeutic drugs show diverse pharmacological actions (such as anti-inflammatory, antioxidant, anti-fibrotic activities), the remarkable tolerance, stability in the systemic circulation which could offer a greater advantage in reducing the risk of COVID-19 induced pathogenesis without much of side effects (Fig. 11 ). As a proof of concept, certain plant-based therapeutics are under different phases of clinical trials.

Fig. 11

The possible multifaceted roles of plant-derived small molecules in inhibiting SARS-CoV-2 mediated lung damage caused by viral replication and its related pathological consequences.

Taken together, this review article provides a summary of diverse mechanisms of action of plant-based therapeutics to mitigate COVID-19. The knowledge obtained here could be applied to further understand the COVID-19 replication cycle and related antiviral mechanisms.

Declaration of competing interest

The authors declare that there is no conflict of interest.

Funding

No funding was involved in the creation of the manuscript.

Ethical approval statement

As this is a review article, ethical approval is not applicable here.

CRediT authorship contribution statement

B. Uma Reddy: Conceptualization, Methodology, Supervision, Validation, Writing – original draft, Writing – review & editing. Nanda Kishore Routhu: Writing – review & editing, Writing – original draft. Anuj Kumar: Conceptualization, Data curation, Methodology, Writing – original draft, Writing – review & editing.

Acknowledgements

We thank Mayra Segura for proofreading and language editing.

Footnotes

Appendix ASupplementary data to this article can be found online at https://doi.org/10.1016/j.micpath.2022.105512.

Appendix A. Supplementary data

The following is the Supplementary data to this article:

Multimedia component 1:
Click here to view.(34K, docx)Multimedia component 1

Data availability

Data derived from public domain resources. No new data was used for the research described in this article.

References

1. Abdelli I., Hassani F., Brikci S.B., Ghalem S. In-silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria. J. Biomol. Struct. Dyn. 2021;39(9):3263–3276. 10.1080/07391102.2020.1763199. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
2. Agagündüz D., Çelik M.N., Dazıroglu M.E.C., Capasso R. Emergent drug and nutrition interactions in COVID-19: a comprehensive narrative review. Nutrients. 2021;13:1550. 10.3390/nu13051550. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
3. Ahmad J., Ikram S., Ahmad F., Rehman I.U., Mushtaq M. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - a drug repurposing study. Heliyon. 2020;6(7) 10.1016/j.heliyon.2020.e04502. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
4. Alam S., Sarker M., Afrin S., Richi F.T., Zhao C., Zhou J.R., Mohamed I.N. Traditional herbal medicines, bioactive metabolites, and plant products against COVI-19: update on clinical trials and mechanism of actions. Front. Pharmacol. 2021;12:671498. 10.3389/fphar.2021.671498. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
5. Alharbi R.A. Structure insights of SARS-CoV-2 open state envelope protein and inhibiting through active phytochemical of ayurvedic medicinal plants from Withania somnifera. Saudi J. Biol. Sci. 2021;28(6):3594–3601. 10.1016/j.sjbs.2021.03.036. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
6. Anil S.M., Shalev N., Vinayaka A.C., Nadarajan S., Namdar D., Belausov E., Shoval I., Mani K.A., Mechrez G., Koltai H. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19 related inflammation in lung epithelial cells and proinflammatory activity in macrophages. Sci. Rep. 2021;11(1):1462. 10.1038/s41598-021-81049-2. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
7. Arokiyaraj S., Stalin A., Kannan B.S., Shin H. Geranii herba as a Potential Inhibitor of SARS-CoV-2 main 3CLpro, spike RBD, and regulation of unfolded protein response: an in-silico approach. Antibiotics (Basel) 2020;9(12):863. 10.3390/antibiotics9120863.PMID.33287311. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
8. Armijos-Jaramillo V., Yeager J., Muslin C., Perez-Castillo Y. SARS-CoV-2, an evolutionary perspective of interaction with human ACE2 reveals undiscovered amino acids necessary for complex stability. Evol. Appl. 2020;13(9):2168–2178. 10.1111/eva.12980. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
9. Al-Horani R.A., Kar S. Potential Anti-SARS-CoV-2 Therapeutics that target the post-entry stages of the viral life cycle: a comprehensive review. Viruses. 2020;12(10):1092. 10.3390/v12101092. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
10. Alazmi M., Motwalli O. Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates. J. Mol. Model. 2020;26(12):338. 10.1007/s00894-020-04599-8. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
11. Alexpandi R., De Mesquita J.F., Pandian S.K., Ravi A.V. Quinolines-based SARS-CoV-2 3CLpro and RdRp inhibitors and spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in-silico analysis. Front. Microbiol. 2020;11:1796. https:// 10.3389/fmicb.2020.01796 [Europe PMC free article] [Abstract] [Google Scholar]
12. Basu A., Sarkar A., Maulik U. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2. Sci. Rep. 2020;10(1):17699. 10.1038/s41598-020-74715-4. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
13. Bestle D., Heindl M.R., Limburg H., Van T.V.L., Pilgram O., Moulton H., Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D., Garten W., Steinmetzer T., Böttcher-Friebertshäuser E. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance. 2020;3(9) 10.26508/lsa.202000786. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
14. Cao R., Hu H., Li Y., Wang X., Xu M., Liu J., Zhang H., Yan Y., Zhao L., Li W., Zhang T., Xiao D., Guo X., Li Y., Yang J., Hu Z., Wang M., Zhong W. Anti-SARS-CoV-2 potential of artimisinins in-vitro. ACS Infect. Dis. 2020;6(9):2524–2531. 10.1021/acsinfecdis.0c00522. [Abstract] [CrossRef] [Google Scholar]
15. Chen Z., Cui Q., Cooper L., Zhang P., Lee H., Chen Z., Wang Y., Liu X., Rong L., Du R. Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases. Cell Biosci. 2021;11(1):45. 10.1186/s13578-021-00564-x. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
16. Chikhale R.V., Sinha S.K., Patil R.B., Prasad S.K., Shakya A., Gurav N., Prasad R., Dhaswadikar S.R., Wanjari M., Gurav S.S. In-silico investigation of phytochemicals from Asparagus racemosus as plausible antiviral agent in COVID-19. J. Biomol. Struct. Dyn. 2020:1–15. 10.1080/07391102.2020.1784289. [Abstract] [CrossRef] [Google Scholar]
17. Chikhale R.V., Gurav S.S., Patil R.B., Sinha S.K., Prasad S.K., Shakya A., Shrivastava S.K., Gurav N.S., Prasad R.S. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach. J. Biomol. Struct. Dyn. 2020:1–12. 10.1080/07391102.2020.1778539. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
18. Chourasia M., Koppula P.R., Battu A., Ouseph M.M., Singh A.K. EGCG, a green tea catechin, as a potential therapeutic agent for symptomatic and asymptomatic SARS-CoV-2 infection. Molecules. 2021;26:1200. 10.3390/molecules26051200. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
19. Coutard B., Valle C., de Lamballerie X., Canard B., Seidah N.G., Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir. Res. 2020;176:104742. 10.1016/j.antiviral.2020.104742. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
20. da Silva F.M.A., da Silva KPA, de Oliveira L.P.M., Costa E.V., Koolen H.H., Pinheiro M.L.B., de Souza A.Q.L., de Souza A.D.L. Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp) Mem. Inst. Oswaldo Cruz. 2020;115 10.1590/0074-02760200207. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
21. Das P., Majumder R., Mandal M., Basak P. In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (M pro) from flavonoid based phytochemical constituents of Calendula officinalis. J. Biomol. Struct. Dyn. 2020:1–16. 10.1080/07391102.2020.1796799. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
22. Ding B., Qin Y., Chen M. Nucleocapsid proteins: roles beyond viral RNA packaging. Wiley Interdiscip. Rev. RNA. 2016;7(2):213–226. 10.1002/wrna.1326. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
23. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R.E., Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000;87(5):E1–E9. 10.1161/01.res.87.5.e1. [Abstract] [CrossRef] [Google Scholar]
24. Elekofehinti O.O., Iwaloye O., Famusiwa C.D., Akinseye O., Rocha J.B.T. Identification of main protease of coronavirus SARS-CoV-2 (Mpro) inhibitors from Melissa officinalis. Curr. Drug Discov. Technol. 2020;17:1–19. 10.2174/1570163817999200918103705. [Abstract] [CrossRef] [Google Scholar]
25. El-Mageed H.R.A., Abdelrheem D.A., Rafi M.O., Sarker M.T., Al-Khafaji K., Hossain M.J., Capasso R., Emran T.B. In silico evaluation of different flavonoids from medicinal plants for their potency against SARS-CoV-2. Biologics. 2021;1:416–434. 10.3390/biologics1030024. [CrossRef] [Google Scholar]
26. Esam Z. Protective potential of expectorants against COVID-19. Med. hypoth. 2020;142:109844–202044. 10.1016/j.mehy.2020.109844. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
27. Fakhar Z., Faramarzi B., Pacifico S., Faramarzi S. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: an in-silico perspective of therapeutic targets against COVID-19 pandemic. J. Biomol. Struct. Dyn. 2020:1–13. 10.1080/07391102.2020.1801510. [Abstract] [CrossRef] [Google Scholar]
28. Gao J., Tian Z., Breakthrough Yang X. Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends. 2020;14:72–73. 10.5582/bst.2020.01047. [Abstract] [CrossRef] [Google Scholar]
29. Glinsky G.V. Tripartite combination of candidate pandemic mitigation agents: vitamin D, quercetin, and estradiol manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defined by genomics-guided tracing of SARS-CoV-2 targets in human cells. Biomedicines. 2020;8(5):129. 10.3390/biomedicines8050129. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
30. Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., Feldt T., Green G., Green M.L., Lescure F.X., Nicastri E., Oda R., Yo K., Quiros-Roldan E., Studemeister A., Redinski J., Ahmed S., Bernett J., Chelliah D., Chen D., Chihara S., Cohen S.H., Cunningham J., D'Arminio-Monforte A., Ismail S., Kato H., Lapadula G., L'Her E., Maeno T., Majumder S., Massari M., Mora-Rillo M., Mutoh Y., Nguyen D., Verweij E., Zoufaly A., Osinusi A.O., DeZure A., Zhao Y., Zhong L., Chokkalingam A., Elboudwarej E., Telep L., Timbs L., Henne I., Sellers S., Cao H., Tan S.K., Winterbourne L., Desai P., Mera R., Gaggar A., Myers R.P., Brainard D.M., Childs R., Flanigan T. Compassionate use of remdesivir for patients with severe covid-19. N. Engl. J. Med. 2020;382(24):2327–2336. 10.1056/NEJMoa2007016. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
31. Gyebi G.A., Ogunro O.B., Adegunloye A.P., Ogunyemi O.M., Afolabi S.O. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL pro): an in-silico screening of alkaloids and terpenoids from African medicinal plants. J. Biomol. Struct. Dyn. 2021;39(9):3396–3408. 10.1080/07391102.2020. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
32. Hilpert K. Is the gut microbiome a target for adjuvant treatment of COVID-19? Biologics. 2021;1:285–299. 10.3390/biologics1030017. [CrossRef] [Google Scholar]
33. Hamming I., Timens W., Bulthuis M., Lely A., Navis G., Goor V.H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203:631–637. 10.1002/path.1570. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
34. Hussain M., Jabeen N., Amanullah A., Baig A.A., Aziz B., Shabbir S., Raza F., Uddin N. Molecular docking between human TMPRSS2 and SARS-CoV-2 spike protein: conformation and intermolecular interactions. AIMS Microb. 2020;6(3):350–360. 10.3934/microbiol.2020021. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
35. Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., Müller M.A., Drosten C., Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280. 10.1016/j.cell.2020.02.052. e8. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
36. Hoffmann M., Kleine-Weber H., Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell. 2020;78(4):779–784. 10.1016/j.molcel.2020.04.022. e5. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
37. Jalali A., Dabaghian F., Akbrialiabad H., Foroughinia F., Zarshenas M.M. A pharmacology-based comprehensive review on medicinal plants and phytoactive constituents possibly effective in the management of COVID-19. Phytother Res. 2020;35(4):1925–1938. 10.1002/ptr.6936. [Abstract] [CrossRef] [Google Scholar]
38. Jan J.T., Cheng T.J.R., Juang Y.P., Ma H.H., Wu Y.T., Yang W.B., Cheng C.W., Chen X., Chou T.H., Shie J.J., Cheng W.C., Chein R.J., Mao S.S., Liang P.H., Ma C., Hung S.C., Wong C.H. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection. Proc. Natl. Acad. Sci. U. S. A. 2021;118(5) 10.1073/pnas.2021579118. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
39. Jang M., Park Y.I., Cha Y.E., Park R., Namkoong S., Lee J.I., Park J. Tea polyphenols EGCG and theaflavin inhibit the activity of SARS-CoV-2 3CL-protease invitro. Evid-Based Compl. Alt. Med. 2000;2020:5630838. 10.1155/2020/5630838. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
40. Joshi S., Joshi M., Degani M.S. Tackling SARS-CoV-2: proposed targets and repurposed drugs. Future Med. Chem. 2020;12(17):1579–1601. 10.4155/fmc-2020-0147. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
41. Kar P., Sharma N.R., Singh B., Sen A., Roy A. Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: an in-silico investigation. J. Biomol. Struct. Dyn. 2020;19:1–12. 10.4155/fmc-2020-0147. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
42. Kanjanasirirat P., Suksatu A., Manopwisedjaroen S., Munyoo B., Tuchinda P., Jearawuttanakul K., Seemakhan S., Charoensutthivarakul S., Wongtrakoongate P., Rangkasenee N., Pitiporn S., Waranuch N., Chabang N., Khemawoot P., Sa-ngiamsuntorn K., Pewkliang Y., Thongsri P., Chutipongtanate S., Hongeng S., Borwornpinyo S. Thitithanyanont A High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents. Sci. Rep. 2020;10:19963. 10.1038/s41598-020-77003-3. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
43. Khaerunnisa S., Kurniawan H., Awaluddin R., Suhartati S., Soetjipto S. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. Preprints. 2020:2020030226. 10.20944/preprints202003.0226.v1. [CrossRef] [Google Scholar]
44. Khan M.A., Khan Z.A., Charles M., Pratap P., Naeem A., Siddiqui Z., Naqvi N., Srivastava S. Cytokine storm and mucus hypersecretion in COVID-19: review of Mechanisms. J. Iflamm Res. 2021;14:175–189. 10.2147/JIR.S271292. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
45. Kirchdoerfer R.N., Ward A.B. Structure of the SARS-CoV NSP12 polymerase bound to NSP7 and NSP8 co-factors. Nat. Commun. 2019;10(1):2342. 10.1038/s41467-019-10280-3. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
46. Kousar K., Majeed A., Yasmin F., Hussain W., Rasool N. Phytochemicals from selective plants have promising potential against SARS-CoV-2: investigation and corroboration through molecular docking, MD simulations, and quantum computations. BioMed Res. Int. 2020:6237160. 10.1155/2020/6237160. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
47. Kulkarni S.A., Nagarajan S.K., Ramesh V., Palaniyandi V., Selvam S.P., Madhavan T. Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein. J. Mol. Struct. 2020;1221:128823. 10.1016/j.molstruc.2020.128823. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
48. Kumar K.J.S., Vani M.G., Wang C.S., Chen C.C., Chen Y.C., Lu L.P., Huang C.H., Lai C.S., Wang S.Y. Geranium and lemon essential oils and their active compounds downregulate angiotensin-converting enzyme 2 (ACE2), a SARS-CoV-2 spike receptor-binding domain, in epithelial cells. Plants. 2020;9(6):770. 10.3390/plants9060770. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
49. Kumar V., Dhanjal J.K., Bhargava P., Kaul A., Wang J., Zhang H., Kaul S.C., Wadhwa R., Sundar D. Withanone and withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells. J. Biomol. Struct. Dyn. 2020:1–13. 10.1016/j.phymed.2020.153317. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
50. Liu H., Ye F., Sun Q., Liang H., Li C., Li S., Lu R., Huang B., Tan W., Lai L. Scutellaria baicalensis extract and baicalin inhibit replication of SARS CoV-2 and its 3C -like protease in-vitro. J. Enzym. Inhib. Med. Chem. 2021;36(1):497–503. 10.1080/14756366.2021.1873977. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
51. Mahmud S., Paul G.K., Afroze M., Islam S., Gupt S.B.R., Razu M.H., Biswas S., Zaman S., Uddin M.S., Khan M., Cacciola N.A., Emran T.B., Saleh M.A., Capasso R., Simal-Gandara J. Efficacy of phytochemicals derived from Avicennia officinalis for the management of COVID-19: a combined in silico and biochemical study. Molecules. 2021;26(8):2210. 10.3390/molecules26082210. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
52. Maiti B.K. Potential role of peptide-based antiviral therapy against SARSCoV-2 infection. ACS Pharmacol. Transl. Sci. 2020;3:783–785. 10.3389/fphar.2020.575444. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
53. Maiti S., Banerjee A. Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: bioinformatics and molecular docking study. Drug Dev. Res. 2020;82(1):86–96. 10.1002/ddr.21730. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
54. Millet J.K., Whittaker G.R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl. Acad. Sci. U.S.A. 2014;111(42):15214–15219. 10.1073/pnas.1407087111. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
55. Mitra D., Verma D., Mahakur B., Kamboj A., Srivastava R., Gupta S., Pandey A., Arora B., Pant K., Panneerselvam P., Ghosh A., Barik D.P., Mohapatra P.K.D. Molecular docking and simulation studies of natural compounds Vitex negundo L. against papain-like protease (PLpro) of SARS CoV-2 (coronavirus) to conquer the pandemic situation in the world. J. Biomol. Struct. Dyn. 2021:1–22. 10.1080/07391102.2021.1873185. [Abstract] [CrossRef] [Google Scholar]
56. Mondal P., Natesh J., Ajees A., Salam A., Thiyagarajan S., Meeran S.M. Traditional medicinal plants against replication, maturation and transmission targets of SARS-CoV-2: computational investigation. J. Biomol. Struct. Dyn. 2020:1–18. 10.1080/07391102.2020.1842246. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
57. Mousavi S.S., Karami A., Haghighi T.M., Tumilaar S.G., Fatimawali, Idroes R., Mahmud S., Celik I., Ağagündüz D., Tallei T.E., Emran T.B., Capasso R. In silico evaluation of Iranian medicinal plant phytoconstituents as inhibitors against main protease and the receptor-binding domain of SARS-CoV-2. Molecules. 2021;26(18):5724. 10.3390/molecules26185724. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
58. Muchtaridi M., Fauzi M., Ikram N.K.K., Gazzali A.M., Wahab H.A. Natural flavonoids as potential angiotensin-converting enzyme 2 inhibitors for anti-SARS-CoV-2. Molecules. 2020;25(17):3980. 10.3390/molecules25173980. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
59. Naqvi A.A.T., Fatima K., Mohammad T., Fatima U., Singh I.K., Singh A., Atif S.M., Hariprasad G., Hasan G.M., Hassan M.I. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 2020;1866(10):165878. 10.1016/j.bbadis.2020.165878. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
60. Ning W., Wang S., Dong X., Liu D., Fu L., Jin R., Xu A. Epigallocatechin-3-gallate (EGCG) suppresses the Trafficking of Lymphocytes to epidermal melanocytes via inhibition of JAK2: its implication for Vitiligo treatment. Biol. Pharm. Bull. 2015;38(11):1700–1706. 10.1248/bpb.b15-00331. [Abstract] [CrossRef] [Google Scholar]
61. Nguyen L.C., Yang D., Nicolaescu V., Best T.J., Gula H., Saxena D., Gabbard J.D., Chen S.N., Ohtsuki T., Friesen J.B., Drayman N., Mohamed A., Dann C., Silva D., Robinson-Mailman L., Valdespino A., Stock L., Suárez E., Jones K.A., Azizi S.A., Demarco J.K., Severson W.E., Anderson C.D., Millis J.M., Dickinson B.C., Tay S., Oakes S.A., Pauli G.F., Palmer K.E., The National COVID Cohort Collaborative Consortium, Meltzer D.O., Randall G., Rosner M.R. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci. Adv. 2022;8(8) 10.1126/sciadv.abi6110. [Abstract] [CrossRef] [Google Scholar]
62. Pandeya K.B., Ganeshpurkar A., Mishra M.K. Natural RNA dependent RNA polymerase inhibitors: molecular docking studies of some biologically active alkaloids of Argemone mexicana. Med. Hypotheses. 2020;144:109905. 10.1016/j.mehy.2020.109905. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
63. Paoloni-Giacobino A., Chen H., Peitsch M.C., Rossier C., Antonarakis S.E. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics. 1997;44(3):309–320. 10.1006/geno.1997.4845. [Abstract] [CrossRef] [Google Scholar]
64. Paramasivam A. RNA 2′-O-methylation modification and its implication in COVID-19 immunity. Cell Death Dis. 2020;6(1):118. 10.1038/s41420-020-00358-z. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
65. Peacock T.P., Goldhill D.H., Zhou J., Baillon L., Frise R., Swann O.C., Kugathasan R., Penn R., Brown J.C., Sanchez-David R.Y., Braga L., Williamson M.K., Hassard J.A., Staller E., Hanley B., Osborn M., Giacca M., Davidson A.D., Matthews D.A., Barclay W.S. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat Microbiol. 2021;6(7):899–909. 10.1038/s41564-021-00908-w. [Abstract] [CrossRef] [Google Scholar]
66. Prasanth D.S.N.B.K., Murahari M., Chandramohan V., Panda S.P., Atmakuri L.R., Guntupalli C. In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2. J. Biomol. Struct. Dyn. 2020:1–15. 10.1080/07391102.2020.1779129. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
67. Qamar M.T.U., Alqahtani S.M., Alamri M.A., Chen L.L. Structural basis of SARS-CoV-2 3CL pro and anti-COVID-19 drug discovery from medicinal plants. J. Pharm. Anal. 2020;10(4):313–319. 10.1016/j.jpha.2020.03.009. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
68. Redondo N., Zaldívar-López S., Garrido J.J., Montoya M. SARS-CoV-2 accessory proteins in viral pathogenesis: knowns and unknowns. Front. Immunol. 2021;12:708264. 10.3389/fimmu.2021.708264. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
69. Rolta R., Yadav R., Salaria D., Trivedi S., Imran M., Sourirajan A., Baumler D.J., Dev K. In-silico screening of hundred phytocompounds of ten medicinal plants as potential inhibitors of nucleocapsid phosphoprotein of COVID-19: an approach to prevent virus assembly. J. Biomol. Struct. Dyn. 2020:1–18. 10.1080/07391102.2020.1804457. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
70. Rosas I.O., Bräu N., Waters M., Go R.C., Hunter B.D., Bhagani S., Skiest D., Aziz M.S., Cooper N., Douglas I.S., Savic S., Youngstein T., Sorbo L.D., Gracian A.C., Zerda D.J.D.L., Ustianowski A., Bao M., Dimonaco S., Graham E., Matharu B., Spotswood H., Tsai L., Malhotra A. Tocilizumab in hospitalized patients with severe covid-19 pneumonia. N. Engl. J. Med. 2021;384(16):1503–1516. 10.1056/NEJMoa2028700. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
71. Russo M., Moccia S., Spagnuolo C., Tedesco I., Russo G.L. Roles of flavonoids against coronavirus infection. Chem. Biol. Interact. 2020;328:109211. 10.1016/j.cbi.2020.109211. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
72. Sa-ngiamsuntorn K., Suksatu A., Pewkliang Y., Thongsri P., Kanjanasirirat P., Manopwisedjaroen S., Charoensutthivarakul S., Wongtrakoongate P., Pitiporn S., Khemawoot P., Chutipongtanate S., Borwornpinyo S., Thitithanyanont A., Hongeng S. Anti-SARS-CoV-2 activity of Andrographis paniculata extract and its major component Andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives. J Nat Prod. 2021;84(4):1261–1270. 10.1021/acs.jnatprod.0c01324. [Abstract] [CrossRef] [Google Scholar]
73. Sharma A., Goyal S., Yadav A.K., Kumar P., Gupta L. In-silico screening of plant-derived antivirals against main protease, 3CL pro and endoribonuclease, NSP15 proteins of SARS-CoV-2. J. Biomol. Struct. Dyn. 2020:1–15. 10.1080/07391102.2020.1808077. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
74. Sarker M.T., Hasan A.Q.F., Rafi M.O., Hossain M.J., El-Mageed H.R.A., Elsapagh R.M., Capasso R., Emran T.B. A comprehensive overview of the newly emerged COVID-19 pandemic: features, origin, genomics, epidemiology, treatment, and prevention. Biologics. 2021;1:357–383. 10.3390/biologics1030021. [CrossRef] [Google Scholar]
75. Sinha S.K., Shakya A., Prasad S.K., Singh S., Gurav N.S., Prasad R.S., Gurav S.S. An in-silico evaluation of different saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets. J. Biomol. Struct. Dyn. 2021;39(9):3244–3255. 10.1080/07391102.2020.1762741. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
76. Snijder E.J., Decroly E., Ziebuhr J. The nonstructural proteins directing coronavirus RNA synthesis and processing. J. Adv. Virus Res. 2016;96:59–126. 10.1016/bs.aivir.2016.08.008. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
77. SoRelle J.A., Itoh T., Peng H., Kanak M.A., Sugimoto K., Matsumoto S., Levy M.F., Lawrence M.C., Naziruddin B. Withaferin A inhibits pro-inflammatory cytokine-induced damage to islets in culture and following transplantation. Diabetologia. 2013;56(4):814–824. 10.1007/s00125-012-2813-9. [Abstract] [CrossRef] [Google Scholar]
78. Su H.X., Yao S., Zhao W.F., Li M.J., Liu J., Shang W.J., Xie H., Ke C.Q., Hu H.C., Gao M.N., Yu K.Q., Liu H., Shen J.S., Tang W., Zhang L.K., Xiao G.F., Ni L., Wang D.W., Zuo J.P., Jiang H.L., Bai F., Wu Y., Ye Y., Xu Y.C. Anti-SARS-CoV-2 activities in-vitro of shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol. Sin. 2020;41:1167–1177. 10.1038/s41401-020-0483-6. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
79. Suručić R., Tubić B., Stojiljković M.P., Djuric D.M., Travar M., Grabež M., Šavikin K., Škrbić R. Computational study of pomegranate peel extract polyphenols as potential inhibitors of SARS-CoV-2 virus internalization. Mol. Cell. Biochem. 2021;476(2):1179–1193. 10.1007/s11010-020-03981-7. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
80. Suručić R., Travar M., Petkovic M., Tubic B., Stojiljković M.P., Grabez M., Savikin K., Zdunic G., Škrbić R. Pomegranate peel extract polyphenols attenuate the SARS-CoV-2 S-glycoprotein binding ability to ACE2 Receptor: in-silico and in-vitro studies. Bioorg. Chem. 2021;114:105145. 10.1016/j.bioorg.2021.105145. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
81. Tallei T.E., Fatimawali, Niode N.J., Idroes R., Redwan Martin Zidan B.M., Mitra S., Celik I., Nainu F., Agagunduz D., Emran T.B., Capasso R. A comprehensive review of the potential use of green tea polyphenols in the management of COVID-19. Evid. Based Complement. Alternat. Med. 2021:7170736. 10.1155/2021/7170736. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
82. Thuy B.T.P., My T.T.A., Hai N.T.T., Hieu L.T., Hoa T.T., Loan H.T.P., Triet N.T., Anh T.T.V., Quy P.T., Tat P.V., Hue N.V., Quang D.T., Trung N.T., Tung V.T., Huynh L.K., Nhung N.T.A. Investigation into SARS-CoV2 resistance of compounds in essential oil. ACS Omega. 2020;5:8312–8320. 10.1021/acsomega.0c00772. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
83. Tong S., Su Y., Yu Y., Wu C., Chen J., Wang S., Jiang J. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int. J. Antimicrob. Agents. 2020;56(3):106114. 10.1016/j.ijantimicag.2020.106114. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
84. Tripathi M.K., Singh P., Sharma S., Singh T.P., Ethayathulla A.S., Kaur P. Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor. J. Biomol. Struct. Dyn. 2020:1–14. 10.1080/07391102.2020.1790425. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
85. Umashankar V., Deshpande S.H., Hegde H.V., Singh I., Chattopadhyay D. Phytochemical moieties from Indian traditional medicine for targeting dual hotspots on SARS-CoV-2 spike protein: an integrative in-silico approach. Front. Med. 2021;8:672629. 10.3389/fmed.2021.672629. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
86. van de Sand L., Bormann M., Alt M., Schipper L., Heilingloh C.S., Steinmann E., Todt D., Dittmer U., Elsner C., Witzke O., Krawczyk A. Glycyrrhizin effectively inhibits SARS-CoV-2 in-vitro by inhibiting the viral main protease. Viruses. 2021;13(4):609. 10.3390/v13040609. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
87. Vardhan S., Sahoo S.K. In-silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19. Comput. Biol. Med. 2020;124:103936. 10.1016/j.compbiomed.2020.103936. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
88. V'kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19(3):155–170. 10.1038/s41579-020-00468-6. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
89. Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J. Virol. 2020;94 10.1128/JVI.00127-20. Print 2020 Mar 17. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
90. Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y., Fu S., Gao L., Cheng Z., Lu Q., Hu Y., Luo G., Wang K., Lu Y., Li H., Wang S., Ruan S., Yang C., Mei C., Wang Y., Ding D., Wu F., Tang X., Ye X., Ye Y., Liu B., Yang J., Yin W., Wang A., Fan G., Zhou F., Liu Z., Gu X., Xu J., Shang L., Zhang Y., Cao L., Guo T., Wan Y., Qin H., Jiang Y., Jaki T., Hayden F.G., Horby P.W., Cao B., Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. 10.1016/S0140-6736(20)31022-9. https://clinicaltrials.gov [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
91. Wen C.C., Kuo Y.H., Jan J.T., Liang P.H., Wang S.Y., Liu H.G., Lee C.K., Chang S.T., Kuo C.J., Lee S.S., Hou C.C., Hsiao P.W., Chien S.C., Shyur L.F., Yang N.S. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J. Med. Chem. 2007;50(17) 10.1021/jm070295s. 4087-95. [Abstract] [CrossRef] [Google Scholar]
92. Wu C., Liu Y., Yang Y., Zhang P., Zhong W., Wang Y., Wang Q., Xu Y., Li M., Li X., Zheng M., Chen L., Li H. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B. 2020;10(5):766–788. 10.1016/j.apsb.2020.02.008. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
93. Yang L.J., Chen R.H., Hamdoun S., Coghi P., Ng J.P.L., Zhang D.W., Guo X., Xia C., Law B.Y.K., Wong V.K.W. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding. Phytomedicine. 2021;87:153591. 10.1016/j.phymed.2021.153591. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
94. Yang H., Yang M., Ding Y., Liu Y., Lou Z., Zhou Z., Sun L., Mo L., Ye S., Pang H., Gao G.F., Anand K., Bartlam M., Hilgenfeld R., Rao Z. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2003;100(23):13190–13195. 10.1073/pnas.1835675100. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
95. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., Liu M.Q., Chen Y., Shen X.R., Wang X., Zheng X.S., Zhao K., Chen Q.J., Deng F., Liu L.L., Yan B., Zhan F.X., Wang Y.Y., Xiao G.F., Shi Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798) 10.1038/s41586-020-2012-7. 270-3. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
96. Zhou R., Zeng R., Brunn Av, Lei J. Structural characterization of the C-terminal domain of SARS-CoV-2 nucleocapsid protein. Mol. Biomed. 2020;1(2):1–11. 10.3389/fmolb.2020.605236. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
97. Raj V., Park J.G., Cho K.H., Choi P., Kim T., Ham J., Lee J. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in -vitro approaches. Int. J. Biol. Macromol. 2021;168:474–485. 10.1016/j.ijbiomac.2020.12.020. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
98. Bachiega T.F., Sforcin J.M. Lemongrass and citral effect on cytokines production by murine macrophages. J. Ethnopharmacol. 2011;137(1):909–913. 10.1016/j.jep.2011.07.021. [Abstract] [CrossRef] [Google Scholar]
99. Dubey S, Yoon H, Cohen M.S., Nagarkatti P, Nagarkatti M, Karan D. Withaferin A associated differential regulation of inflammatory cytokines. Front. Immunol. 2018;9(195):1–10. 10.3389/fimmu.2018.00195. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
100. Dhanasekaran S., Pradeep P.S. Scope of phytotherapeutics in targeting ACE2 mediated Host-Viral Interface of SARS‐CoV2 that causes COVID-19. ChemRxiv. 2020 10.26434/chemrxiv.12089730.v1. [CrossRef] [Google Scholar]
101. Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in-silico docking and molecular dynamics simulation study. J. Biomol. Struct. Dyn. 2020:1–13. 10.1080/07391102.2020.1779818. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
102. Jiang Y., Zhou Z., Meng Q.T., Sun Q., Su W., Lei S., Xia Z., Xia Z.Y. Ginsenoside Rb1 treatment attenuates pulmonary inflammatory cytokine release and tissue injury following intestinal ischemia reperfusion injury in mice. Oxid. Med. Cell. Longev. 2015:843721. 10.1155/2015/843721. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
103. Jo S., Kim S, Kim D.Y., Kim M.S., Shin D.H. Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro. J. Enzyme Inhib. Med. Chem. 2020;35(1):1539–1544. 10.1080/14756366.2020.1801672. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
104. Ka S.M., Lin J.C., Lin T.J., Liu F.C., Chao L.K., Ho C.L., Yeh L.T., Sytwu H.K., Hua K.F., Chen A. Citral alleviates an accelerated and severe lupus nephritis model by inhibiting the activation signal of NLRP3 inflammasome and enhancing Nrf2 activation. Arthritis Res. Ther. 2015;17:331. 10.1186/s13075-015-0844-6. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
105. Kempuraj D., Madhappan B., Christodoulou S., Boucher W., Cao J., Papadopoulou N., Cetrulo C.L., Theoharides T.C. Flavonols inhibit pro-inflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br. J. Pharmacol. 2005;145(7):934–944. [Europe PMC free article] [Abstract] [Google Scholar]
106. Kumar S, Kashyap P, Chowdhury S, Kumar S, Panwar A, Kumar A. Identification of phytochemicals as potential therapeutic agents that binds to NSP15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication. Phytomedicine. 2021;85:153317. 10.3390/plants9060770. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
107. Kuzikov M., Costanzi E., Reinshagen J., Esposito F., Vangeel L., Wolf M., Ellinger B., Claussen C., Geisslinger G., Iaconis D., Talarico C., Manelfi C., Cannalire R., Rossetti G., Gossen J., Albani S., Musiani F., Herzog K., Ye Y., Giabbai B., Demitri N., Jochmans D., Jonghe S.D., Rymenants J., Summa V., Tramontano E., Beccari A.R., Leyssen P., Storici P., Neyts J., Gribbon P., Zaliani A. Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen. ACS Pharmacol. Transl. Sci. 2021.;4(3):1096–1110. 10.1021/acsptsci.0c00216. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
108. Li Q., Yi D., Lei X., Lei X., Zhao J., Zhang Y., Cui X., Xiao X., Jiao T., Dong X., Zhao X.., Zeng H., Liang C., Ren L., Guo F., Li X., Wang J., Cen S. Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase. Acta. Pharm. Sin. B. 2021;11(6):1555–1567. [Europe PMC free article] [Abstract] [Google Scholar]
109. Majumder R., Mandal M. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an in silico docking and molecular dynamics simulation approach. J. Biomol. Struct. Dyn. 2020:1–16. 10.1016/j.arabjc.2021.103315. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
110. Cho J., Lee Y.J., Kim J.H., Kim S.I., Kim S.S., Choi B.S., Choi J.H. Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19. Sci Rep. 2020;10:16200. 10.1038/s41598-020-72879-7. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
111. Choy K.T., Wong A.Y.L., Kaewpreedee P., Sia S.F., Chen D., Hui K.P.Y., Chu D.K.W., Chan M.C.W., Cheung P.P.H., Huang X., Peiris M., Yen H.L. Remdesivir, lopinavir, emetine and homoharringtonine inhibit SARS-CoV-2 replication in-vitro. Anitiviral Res. 2020;178:104786. 10.1016/j.antiviral.2020.104786. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
112. Jin Y.H., Min J.S., Jeon S., Lee J., Kim S., Park T, Park D., Jang M.S., Park C.M., Song J.H., Kim H.R., Kwon S. Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections. Phytomedicine. 2020;86:153440. 10.1016/j.phymed.2020.153440. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
113. Ma Q., Li R., Pan W., Huang W., Liu B., Xie Y, Wang Z., Li C., Jiang H., Huang J., Shi Y., Dai J., Zheng K., Li X., Hui M., Fu L., Yang Z. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway. Phytomedicine. 2020;78:153296. 10.1016/j.phymed.2020.153296. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
114. Ohashi H., Watashi K., Saso W., Shionoya K., Iwanami S., Hirokawa T., Shirai T., Kanaya S., Ito Y., Kim K.S., Nomura T., Suzuki T., Nishioka K., Ando S., Ejima K., Koizumi Y., Tanaka T., Aoki S., Kuramochi K., Suzuki T., Hashiguchi T., Maenaka K., Matano T., Muramatsu M., Saijo M., Aihara K., Iwami S., Takeda M., McKeating J.A., Wakita T. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience. 2021;24:102367. 10.1016/j.isci.2021.102367. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
115. Park J.Y., Kim J.H., Kim Y.M., Jeong H.J., Kim D.W., Park K.H., Kwon H.J., Park S.J., Lee W.S., Ryu Y.B. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases. Bioorg Med Chem. 2012;20(19):5928–5935. 10.1016/j.bmc.2012.07.038. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
116. Kim D., Lee J-Y., Yang J-S., Kim J-W., Kim V.N., Chang H. The architecture of SARS-CoV-2 transcriptome. bioRxiv. 2020 10.1101/2020.03.12.988865. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
117. de Vries A.A.F. SARS-CoV-2/ COVID-19:a primer for cardiologists. Neth Heart J. 2020;28:366–383. 10.1007/s12471-020-01475-1. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
118. Bian J, Li Z. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharmaceutica Sinica B. 2021:1–12. 10.1016/j.apsb.2020.10.006. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
119. Mahmoud I.S., Jarrar Y.B. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges. Molecular Biology Reports. 2021:4667–46754675. 10.1007/s11033-021-06390-1. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
120. Zhang W-F., Stephen P, Theriaul J-F., Wang R., Lin S-X. Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks. J. Phys Chem Lett. 2020:4430–4435. 10.1021/acs.jpclett.0c00571. [Abstract] [CrossRef] [Google Scholar]
121. Fairman-Williams Margaret E, Guenther Ulf-Peter, Jankowsky Eckhard. SF1 and SF2 helicases: family matters. Curr Opin Struct Biol. 2010:313–324. 10.1016/j.sbi.2010.03.011. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
122. Bar-On Y.M., Flamholz A., Phillips R., Milo R. SARS-CoV-2 (COVID-19) by the numbers. Elife. 2020;9 10.7554/eLife.57309. e57309. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]

Citations & impact 


Impact metrics

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/126026791
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/126026791

Article citations

Data 


Data behind the article

This data has been text mined from the article, or deposited into data resources.

Funding 


Funders who supported this work.

NIH HHS (1)